1
|
c-Myc-Regulated lncRNA-IGFBP4 Suppresses Autophagy in Cervical Cancer-Originated HeLa Cells. DISEASE MARKERS 2022; 2022:7240646. [PMID: 36072894 PMCID: PMC9444448 DOI: 10.1155/2022/7240646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 07/19/2022] [Indexed: 11/17/2022]
Abstract
LncRNAs are known to regulate a plethora of key events of cellular processes; however, little is known about the function of lncRNAs in autophagy. Here in the current study, we report lncRNA-IGFBP4 which has previously been known to regulate the proliferation and reprogramming of cancer cells, but its role in autophagy is not yet known. We found that serum starvation provokes autophagy-induced downregulation of lncRNA-IGFBP4 levels. Next, we determined that c-Myc can negatively regulate lncRNA-IGFBP4 in HeLa cells. Phenotypically, we found that upon depletion of lncRNA-IGFBP4, the HeLa cells undergo autophagy through ULK1/Beclin1 signaling. Furthermore, through TCGA data analysis, we found lncRNA-IGFB4 overexpressed in most cancers including cervical cancer. Based on these findings, we conclude that c-Myc maintains cellular homeostasis through negatively regulating lncRNA-IGFBP4 in cervical cancer cells.
Collapse
|
2
|
Ng EFY, Kaida A, Nojima H, Miura M. Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Sci Rep 2022; 12:11503. [PMID: 35798794 PMCID: PMC9262895 DOI: 10.1038/s41598-022-15737-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Accepted: 06/28/2022] [Indexed: 11/20/2022] Open
Abstract
Insulin-like growth factor binding protein-3 (IGFBP-3) is a member of the IGFBP family that has high affinity for IGFs and functions as either an oncogene or tumor suppressor in various types of cancer. We previously found that IGFBP3 mRNA levels are higher in endophytic-type human tongue squamous cell carcinoma (TSCC) that is more invasive and more prone to metastasis than exophytic and superficial types. This finding prompted us to investigate the roles of IGFBP-3 in TSCC using SAS cells, which were originally derived from endophytic-type TSCC. Specifically, we used SAS cells that express a fluorescent ubiquitination-based cell-cycle indicator (Fucci). RNA-sequencing analysis indicated that IGFBP-3 is associated with cell migration and cell growth. In fact, IGFBP-3 knockdown downregulates cell migration and causes cells to arrest in G1. This migratory potential appears to be cell cycle–independent. IGFBP-3 knockdown also reduced levels of secreted IGFBP-3; however, decreased migratory potential was not rescued by exogenous recombinant human IGFBP-3. Furthermore, ERK activity was downregulated by IGFBP-3 depletion, which suggests that MEK/ERK signaling may be involved in IGFBP-3-mediated cell migration. We therefore conclude that intracellular IGFBP-3 enhances cell migration independently of the cell cycle in TSCC with a higher metastatic potential.
Collapse
Affiliation(s)
- Esther Feng Ying Ng
- Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical & Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8549, Japan
| | - Atsushi Kaida
- Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical & Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8549, Japan.
| | - Hitomi Nojima
- Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical & Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8549, Japan
| | - Masahiko Miura
- Department of Oral Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical & Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8549, Japan.
| |
Collapse
|
3
|
Li S, Kim HE. Implications of Sphingolipids on Aging and Age-Related Diseases. FRONTIERS IN AGING 2022; 2:797320. [PMID: 35822041 PMCID: PMC9261390 DOI: 10.3389/fragi.2021.797320] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Accepted: 12/31/2021] [Indexed: 01/14/2023]
Abstract
Aging is a process leading to a progressive loss of physiological integrity and homeostasis, and a primary risk factor for many late-onset chronic diseases. The mechanisms underlying aging have long piqued the curiosity of scientists. However, the idea that aging is a biological process susceptible to genetic manipulation was not well established until the discovery that the inhibition of insulin/IGF-1 signaling extended the lifespan of C. elegans. Although aging is a complex multisystem process, López-Otín et al. described aging in reference to nine hallmarks of aging. These nine hallmarks include: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Due to recent advances in lipidomic, investigation into the role of lipids in biological aging has intensified, particularly the role of sphingolipids (SL). SLs are a diverse group of lipids originating from the Endoplasmic Reticulum (ER) and can be modified to create a vastly diverse group of bioactive metabolites that regulate almost every major cellular process, including cell cycle regulation, senescence, proliferation, and apoptosis. Although SL biology reaches all nine hallmarks of aging, its contribution to each hallmark is disproportionate. In this review, we will discuss in detail the major contributions of SLs to the hallmarks of aging and age-related diseases while also summarizing the importance of their other minor but integral contributions.
Collapse
Affiliation(s)
- Shengxin Li
- Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, TX, United States
- Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Hyun-Eui Kim
- Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, TX, United States
- Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, United States
| |
Collapse
|
4
|
Varma Shrivastav S, Bhardwaj A, Pathak KA, Shrivastav A. Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3): Unraveling the Role in Mediating IGF-Independent Effects Within the Cell. Front Cell Dev Biol 2020; 8:286. [PMID: 32478064 PMCID: PMC7232603 DOI: 10.3389/fcell.2020.00286] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Accepted: 04/02/2020] [Indexed: 12/22/2022] Open
Abstract
Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3), one of the six members of the IGFBP family, is a key protein in the IGF pathway. IGFBP-3 can function in an IGF-dependent as well as in an IGF-independent manner. The IGF-dependent roles of IGFBP-3 include its endocrine role in the delivery of IGFs from the site of synthesis to the target cells that possess IGF receptors and the activation of associated downstream signaling. IGF-independent role of IGFBP-3 include its interactions with the proteins of the extracellular matrix and the proteins of the plasma membrane, its translocation through the plasma membrane into the cytoplasm and into the nucleus. The C-terminal domain of IGFBP-3 has the ability to undergo cell penetration therefore, generating a short 8-22-mer C-terminal domain peptides that can be conjugated to drugs or genes for effective intracellular delivery. This has opened doors for biotechnological applications of the molecule in molecular medicine. The aim of this this review is to summarize the complex roles of IGFBP-3 within the cell, including its mechanisms of cellular uptake and its translocation into the nucleus, various molecules with which it is capable of interacting, and its ability to regulate IGF-independent cell growth, survival and apoptosis. This would pave way into understanding the modus operandi of IGFBP-3 in regulating IGF-independent processes and its pleiotropic ability to bind with potential partners thus regulating several cellular functions implicated in metabolic diseases, including cancer.
Collapse
Affiliation(s)
- Shailly Varma Shrivastav
- VastCon Inc., Winnipeg, MB, Canada.,Department of Biology, University of Winnipeg, Winnipeg, MB, Canada
| | - Apurva Bhardwaj
- Department of Biology, University of Winnipeg, Winnipeg, MB, Canada
| | - Kumar Alok Pathak
- Research Institute of Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.,Department of Surgery, University of Manitoba, Winnipeg, MB, Canada
| | - Anuraag Shrivastav
- Department of Biology, University of Winnipeg, Winnipeg, MB, Canada.,Research Institute of Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
5
|
Steffensen LB, Conover CA, Oxvig C. PAPP-A and the IGF system in atherosclerosis: what's up, what's down? Am J Physiol Heart Circ Physiol 2019; 317:H1039-H1049. [PMID: 31518159 DOI: 10.1152/ajpheart.00395.2019] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1) from IGF-binding protein-2, -4, and -5 by proteolytic processing of these. The IGF system has repeatedly been suggested to be involved in the pathology of atherosclerosis, and both PAPP-A and IGF-1 are proposed biomarkers and therapeutic targets for this disease. Several experimental approaches based on atherosclerosis mouse models have been undertaken to obtain causative and mechanistic insight to the role of these molecules in atherogenesis. However, reports seem conflicting. The literature suggests that PAPP-A is detrimental, while IGF-1 is beneficial. This raises important questions that need to be addressed. Here we summarize the various studies and discuss potential underlying explanations for this seemingly inconsistency with the objective of better understanding complexities and limitations when manipulating the IGF system in mouse models of atherosclerosis. A debate clarifying what's up and what's down is highly warranted going forward with the ultimate goal of improving atherosclerosis therapy by targeting the IGF system.
Collapse
Affiliation(s)
- Lasse B Steffensen
- Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark
| | | | - Claus Oxvig
- Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
| |
Collapse
|
6
|
Jęśko H, Stępień A, Lukiw WJ, Strosznajder RP. The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration. Mol Neurobiol 2019; 56:3501-3521. [PMID: 30140974 PMCID: PMC6476865 DOI: 10.1007/s12035-018-1286-3] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 07/25/2018] [Indexed: 12/20/2022]
Abstract
Bioactive sphingolipids: sphingosine, sphingosine-1-phosphate (S1P), ceramide, and ceramide-1-phosphate (C1P) are increasingly implicated in cell survival, proliferation, differentiation, and in multiple aspects of stress response in the nervous system. The opposite roles of closely related sphingolipid species in cell survival/death signaling is reflected in the concept of tightly controlled sphingolipid rheostat. Aging has a complex influence on sphingolipid metabolism, disturbing signaling pathways and the properties of lipid membranes. A metabolic signature of stress resistance-associated sphingolipids correlates with longevity in humans. Moreover, accumulating evidence suggests extensive links between sphingolipid signaling and the insulin-like growth factor I (IGF-I)-Akt-mTOR pathway (IIS), which is involved in the modulation of aging process and longevity. IIS integrates a wide array of metabolic signals, cross-talks with p53, nuclear factor κB (NF-κB), or reactive oxygen species (ROS) and influences gene expression to shape the cellular metabolic profile and stress resistance. The multiple connections between sphingolipids and IIS signaling suggest possible engagement of these compounds in the aging process itself, which creates a vulnerable background for the majority of neurodegenerative disorders.
Collapse
Affiliation(s)
- Henryk Jęśko
- Department of Cellular Signalling, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Pawińskiego, 5, 02-106, Poland
| | - Adam Stępień
- Central Clinical Hospital of the Ministry of National Defense, Department of Neurology, Military Institute of Medicine, Warsaw, Szaserów, 128, 04-141, Poland
| | - Walter J Lukiw
- LSU Neuroscience Center and Departments of Neurology and Ophthalmology, Louisiana State University School of Medicine, New Orleans, USA
| | - Robert P Strosznajder
- Laboratory of Preclinical Research and Environmental Agents, Department of Neurosurgery, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Pawińskiego, 5, 02-106, Poland.
| |
Collapse
|
7
|
Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Horm IGF Res 2018; 41:7-22. [PMID: 29864720 DOI: 10.1016/j.ghir.2018.05.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 05/15/2018] [Accepted: 05/29/2018] [Indexed: 02/07/2023]
Abstract
Insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) is a modulator of the IGF system, exerting both inhibitory and stimulatory effects on IGF-induced cellular growth. IGFBP-4 is the principal substrate for the enzyme pregnancy-associated plasma protein-A (PAPP-A). Through IGF-dependent cleavage of IGFBP-4 in the vicinity of the IGF receptor, PAPP-A is able to increase IGF bioavailability and stimulate IGF-mediated growth. Recently, the stanniocalcins (STCs) were identified as novel inhibitors of PAPP-A proteolytic activity, hereby adding additional members to the seemingly endless list of proteins belonging to the IGF family. Our understanding of these proteins has advanced throughout recent years, and there is evidence to suggest that the role of IGFBP-4 and PAPP-A in defining the relationship between total IGF and IGF bioactivity can be linked to a number of pathological conditions. This review provides an overview of the experimental and clinical findings on the IGFBP-4/PAPP-A/STC axis as a regulator of IGF activity and examines the conundrum surrounding extrapolation of circulating concentrations to tissue action of these proteins. The primary focus will be on the biological significance of IGFBP-4 and PAPP-A in normal physiology and in pathophysiology with emphasis on metabolic disorders, cardiovascular diseases, and cancer. Finally, the review assesses current new trajectories of IGFBP-4 and PAPP-A research.
Collapse
Affiliation(s)
- Rikke Hjortebjerg
- Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark; The Danish Diabetes Academy, Odense, Denmark.
| |
Collapse
|
8
|
Abstract
Insulin-like growth factor-binding proteins (IGFBPs) 1-6 bind IGFs but not insulin with high affinity. They were initially identified as serum carriers and passive inhibitors of IGF actions. However, subsequent studies showed that, although IGFBPs inhibit IGF actions in many circumstances, they may also potentiate these actions. IGFBPs are widely expressed in most tissues, and they are flexible endocrine and autocrine/paracrine regulators of IGF activity, which is essential for this important physiological system. More recently, individual IGFBPs have been shown to have IGF-independent actions. Mechanisms underlying these actions include (i) interaction with non-IGF proteins in compartments including the extracellular space and matrix, the cell surface and intracellular space, (ii) interaction with and modulation of other growth factor pathways including EGF, TGF-β and VEGF, and (iii) direct or indirect transcriptional effects following nuclear entry of IGFBPs. Through these IGF-dependent and IGF-independent actions, IGFBPs modulate essential cellular processes including proliferation, survival, migration, senescence, autophagy and angiogenesis. They have been implicated in a range of disorders including malignant, metabolic, neurological and immune diseases. A more complete understanding of their cellular roles may lead to the development of novel IGFBP-based therapeutic opportunities.
Collapse
Affiliation(s)
- L A Bach
- Department of Medicine (Alfred)Monash University, Melbourne, Australia
- Department of Endocrinology and DiabetesAlfred Hospital, Melbourne, Australia
| |
Collapse
|
9
|
Hawsawi Y, Humphries MP, Wright A, Berwick A, Shires M, Al-Kharobi H, El-Gendy R, Jove M, Twelves C, Speirs V, Beattie J. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro. Oncotarget 2017; 7:32129-43. [PMID: 27050076 PMCID: PMC5078002 DOI: 10.18632/oncotarget.8534] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 03/14/2016] [Indexed: 12/28/2022] Open
Abstract
Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive breast cancer. Resistance and recurrence remain, however, a major challenge with many women relapsing and subsequently dying. The insulin-like growth factor (IGF) axis is involved in breast cancer pathogenesis and progression to endocrine resistant disease, but there is very little data on the expression and potential role of IGF-binding proteins (IGFBP) during acquisition of the resistant phenotype. The aim of this study was to determine the expression and functional role of IGFBP-2 and -5 in the development of TAM resistance (TamR) in vitro and to test retrospectively whether they were predictive of resistance in a tissue microarray of 77 women with primary breast cancers who relapsed on/after endocrine therapy and 193 who did not with long term follow up. Reciprocal expression of IGFBP-2 and IGFBP-5 was observed at both mRNA and protein level in TamR cells. IGFBP-2 expression was increased by 10-fold while IGFBP-5 was decreased by 100-fold, compared to TAM-sensitive control cells. shRNA-mediated silencing of IGFBP-2 in TamR cells restored TAM sensitivity suggesting a causal role for this gene in TamR. While silencing of IGFBP-5 in control cells had no effect on TAM sensitivity, it significantly increased the migratory capacity of these cells. Quantitative image analysis of immunohistochemical data failed, however, to demonstrate an effect of IGFBP2 expression in endocrine-relapsed patients. Likewise, IGFBP-2 and IGFBP-5 expression failed to show any significant associations with survival either in patients relapsing or those not relapsing on/after endocrine therapy. By contrast, in silico mining of a separate published dataset showed that in patients who received endocrine treatment, loss of expression of IGBP-5 was significantly associated with worse survival. Overall these data suggest that co-ordinated and reciprocal alteration in IGFBP-2 and −5 expression may play a role in the acquisition of endocrine resistance.
Collapse
Affiliation(s)
- Yousef Hawsawi
- Department of Oral Biology, St James's University Hospital, Leeds, UK.,Leeds Institute of Cancer and Pathology, University of Leeds, UK.,Current address: Department of Breast Medical Oncology, MD Anderson Cancer Centre, University of Texas, Houston, USA
| | | | - Alexander Wright
- Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Angelene Berwick
- Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Mike Shires
- Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Hanaa Al-Kharobi
- Department of Oral Biology, St James's University Hospital, Leeds, UK
| | - Reem El-Gendy
- Department of Oral Biology, St James's University Hospital, Leeds, UK
| | - Maria Jove
- St James's Institute of Oncology, St James's University Hospital, Leeds, UK
| | - Chris Twelves
- St James's Institute of Oncology, St James's University Hospital, Leeds, UK.,Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Valerie Speirs
- Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - James Beattie
- Department of Oral Biology, St James's University Hospital, Leeds, UK
| |
Collapse
|
10
|
Yang B, Zhang L, Cao Y, Chen S, Cao J, Wu D, Chen J, Xiong H, Pan Z, Qiu F, Chen J, Ling X, Yan M, Huang S, Zhou S, Li T, Yang L, Huang Y, Lu J. Overexpression of lncRNA IGFBP4-1 reprograms energy metabolism to promote lung cancer progression. Mol Cancer 2017; 16:154. [PMID: 28946875 PMCID: PMC5613386 DOI: 10.1186/s12943-017-0722-8] [Citation(s) in RCA: 94] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 09/12/2017] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Reprogrammed energy metabolism as an emerging hallmark of cancer has recently drawn special attention since it facilitate cell growth and proliferation. Recently, long noncoding RNAs (lncRNAs) have been served as key regulators implicated in tumor development and progression by promoting proliferation, invasion and metastasis. However, the associations of lncRNAs with cellular energy metabolism in lung cancer (LC) need to be clarified. METHODS Here, we conducted bioinformatics analysis and found insulin-like growth factor binding protein 4-1 (IGFBP4-1) as a new candidate lncRNA located in the upstream region of IGFBP4 gene. The expression levels of lnc-IGFBP4-1, mRNA levels of IGFBP4 in 159 paired lung cancer samples and adjacent, histological normal tissues by qRT-PCR. Over-expression and RNA interference (RNAi) approaches were adopted to investigate the biological functions of lnc-IGFBP4-1. The intracellular ATP level was measured using the Cell Titer-Glo Luminescent Cell Viability Assay kit, and changes in metabolic enzymes were examined in cancer cells and normal pulmonary epithelial cells with qRT-PCR. RESULTS Our results showed that lnc-IGFBP4-1 was significantly up-regulated in LC tissues compared with corresponding non-tumor tissues (P < 0.01), and its expression level was significantly correlated with TNM stage (P < 0.01) and lymph node metastasis (P < 0.05). Further investigation showed that overexpression of lnc-IGFBP4-1 significantly promoted LC cell proliferation in vitro and in vivo, while downregulation of endogenous lnc-IGFBP4-1 could inhibited cell proliferation and induce apoptosis. Moreover, we found lnc-IGFBP4-1 could influences ATP production levels and expression of enzymes including HK2, PDK1 and LDHA, in addition, decline in both ATP production and these enzymes in response to 2-DG and 2-DG-combined Rho123, respectively, was observed in lnc-IGFBP4-1-overespressing LC cells, indicative of an enhanced aerobic glycolysis rate. Finally, lnc-IGFBP4-1 was observed to negatively correlate with gene IGFBP4, and lower expression level of IGFPB4 was found after lnc-IGFBP4-1-overexpression was transfected into PC9 cells, higher expression level of IGFPB4 was also found after lnc-IGFBP4-1-downregulation was transfected into GLC-82 cells, which indicates that IGFBP4 may exert its targeting function regulated by lnc-IGFBP4-1. CONCLUSIONS Taken together, these findings provide the first evidence that lnc-IGFBP4-1 is significantly up-regulated in LC tissues and plays a positive role in cell proliferation and metastasis through possible mechanism of reprogramming tumor cell energy metabolism, which suggests that lnc-IGFBP4-1 may be a promising biomarker in LC development and progression and as a potential therapeutic target for LC intervention.
Collapse
Affiliation(s)
- Binyao Yang
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China.,Department of Central Laboratory, The 5th Affiliated Hospital of Guanzhou Medical University, Guangzhou, 510700, China
| | - Lisha Zhang
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Yi Cao
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Shuai Chen
- Yunnan Province Tumor Hospital, the Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China
| | - Jun Cao
- The First People's Hospital of Qujing, Qujing, 655000, China
| | - Di Wu
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Jiansong Chen
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Huali Xiong
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Zihua Pan
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Fuman Qiu
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Jinbin Chen
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Xiaoxuan Ling
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Maosheng Yan
- Guangdong Province Hospital for Occupational Disease Prevention and Treatment, 68 Haikang Road, Guangzhou, 510300, China
| | - Suli Huang
- Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China
| | - Shiyu Zhou
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Tiegang Li
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Lei Yang
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China
| | - Yunchao Huang
- Yunnan Province Tumor Hospital, the Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China
| | - Jiachun Lu
- The State Key Lab of Respiratory Disease, The institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China.
| |
Collapse
|
11
|
Crismale-Gann C, Stires H, Katz TA, Cohick WS. Tumor Phenotype and Gene Expression During Early Mammary Tumor Development in Offspring Exposed to Alcohol In Utero. Alcohol Clin Exp Res 2016; 40:1679-90. [PMID: 27373230 PMCID: PMC4961575 DOI: 10.1111/acer.13139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 05/27/2016] [Indexed: 01/21/2023]
Abstract
BACKGROUND Alcohol exposure in utero increases susceptibility to carcinogen-induced mammary tumorigenesis in adult offspring and causes tumors with a more malignant phenotype. This study was conducted to identify changes early in tumor development that might lead to this outcome. METHODS Pregnant Sprague-Dawley rats were fed a liquid diet containing 6.7% ethanol (alcohol), an isocaloric liquid diet without alcohol (pair-fed), or rat chow ad libitum (ad lib) from gestation day 7 until parturition. At birth, female progeny were cross-fostered to control dams. Pups were weaned at postnatal day (PND) 21 and fed rat chow ad libitum for the remainder of the experiment. Female offspring were administered N-nitroso-N-methylurea (NMU; 50 mg/kg body weight) on PND 50. Mammary glands were palpated weekly, and offspring were euthanized at 16 weeks post-NMU injection. RESULTS At 16 weeks post-NMU, tumor multiplicity was greater in alcohol-exposed offspring compared with control groups. Estrogen receptor-α (ER) mRNA expression was decreased in tumors from alcohol-exposed offspring, and these animals developed more ER-negative tumors relative to the pair-fed group. Alcohol-exposed offspring also tended to develop more progesterone receptor (PR)-positive tumors. All tumors were HER2-negative. PR positivity was associated with higher Ki67 expression, suggesting that PR-positive tumors were more proliferative. Tumors from alcohol-exposed animals exhibited increased mRNA expression of the insulin-like growth factor (IGF) family members IGF-II and IGFBP-5. IGF-II and DNA methyltransferase mRNA tended to be greater in the normal contralateral mammary glands of these animals. CONCLUSIONS These data indicate that alcohol exposure in utero may shift NMU-induced tumor development toward a more aggressive phenotype and that alterations in IGF-II expression may contribute to these changes. Additional studies should be aimed at epigenetic mechanisms that underlie IGF-II expression to further delineate how this gene is altered in mammary glands of adults exposed to alcohol in utero.
Collapse
Affiliation(s)
- Catina Crismale-Gann
- Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
| | - Hillary Stires
- Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
| | - Tiffany A Katz
- Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
| | - Wendie S Cohick
- Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, New Jersey
| |
Collapse
|
12
|
Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of Signaling Pathways in Fourteen Breast Cancer Cell Lines Using Reverse-Phase Protein Lysate Microarray. Technol Cancer Res Treat 2016; 5:543-51. [PMID: 17121430 DOI: 10.1177/153303460600500601] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Signal transduction pathways play a crucial role in breast cancer development, progression, and response to different therapies. A major problem in breast cancer therapy is the heterogeneity among different tumor types and cell lines commonly used in preclinical studies. To characterize the signaling pathways of some of the commonly used breast cancer cell lines and dissect the relationship among a number of pathways and some key genetic and molecular events in breast cancer development, such as p53 mutation, ErbB2 expression, and estrogen receptor (ER)/progesterone receptor (PR) status, we performed pathway profiling of 14 breast cancer cell lines by measuring the expression and phosphorylation status of 40 different cell signaling proteins with 53 specific antibodies using a protein lysate array. Cluster analysis of the expression data showed that there was close clustering of phosphatidylinositol 3-kinase, Akt, mammalian target of rapamycin (mTOR), Src, and platelet-derived growth factor receptor β (PDGFRβ) in all of the cell lines. The most differentially expressed proteins between ER- and PR-positive and ER- and PR-negative breast cells were mTOR, Akt (pThr308), PDGFRβ, PDGFRβ (pTyr751), panSrc, Akt (pSer473), insulin-like growth factor-binding protein 5 (IGFBP5), Src (pTyr418), mTOR (pSer2448), and IGFBP2. Many apoptotic proteins, such as apoptosis-inducing factor, IGFBP3, bad, bax, and cleaved caspase 9, were overexpressed in mutant p53-carrying breast cancer cells. Hexokinase isoenzyme 1, ND2, and c-kit were the most differentially expressed proteins in high and low ErbB2-expressing breast cancer cells. This study demonstrated that ER/PR status, ErbB2 expression, and p53 status are major molecules that impact downstream signaling pathways.
Collapse
Affiliation(s)
- M Akkiprik
- Department of Pathology, Unit 85, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Identification of Differentially Expressed IGFBP5-Related Genes in Breast Cancer Tumor Tissues Using cDNA Microarray Experiments. Genes (Basel) 2015; 6:1201-14. [PMID: 26569312 PMCID: PMC4690035 DOI: 10.3390/genes6041201] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Revised: 11/02/2015] [Accepted: 11/05/2015] [Indexed: 01/02/2023] Open
Abstract
IGFBP5 is an important regulatory protein in breast cancer progression. We tried to identify differentially expressed genes (DEGs) between breast tumor tissues with IGFBP5 overexpression and their adjacent normal tissues. In this study, thirty-eight breast cancer and adjacent normal breast tissue samples were used to determine IGFBP5 expression by qPCR. cDNA microarrays were applied to the highest IGFBP5 overexpressed tumor samples compared to their adjacent normal breast tissue. Microarray analysis revealed that a total of 186 genes were differentially expressed in breast cancer compared with normal breast tissues. Of the 186 genes, 169 genes were downregulated and 17 genes were upregulated in the tumor samples. KEGG pathway analyses showed that protein digestion and absorption, focal adhesion, salivary secretion, drug metabolism-cytochrome P450, and phenylalanine metabolism pathways are involved. Among these DEGs, the prominent top two genes (MMP11 and COL1A1) which potentially correlated with IGFBP5 were selected for validation using real time RT-qPCR. Only COL1A1 expression showed a consistent upregulation with IGFBP5 expression and COL1A1 and MMP11 were significantly positively correlated. We concluded that the discovery of coordinately expressed genes related with IGFBP5 might contribute to understanding of the molecular mechanism of the function of IGFBP5 in breast cancer. Further functional studies on DEGs and association with IGFBP5 may identify novel biomarkers for clinical applications in breast cancer.
Collapse
|
14
|
Abstract
Insulin-like growth factor binding proteins (IGFBPs) 4-6 have important roles as modulators of IGF actions. IGFBP-4 and IGFBP-6 predominantly inhibit IGF actions, whereas IGFBP-5 may enhance these actions under some circumstances. IGFBP-6 is unique among the IGFBPs for its marked IGF-II binding preference. IGFBPs 4-6 are found in the circulation as binary complexes with IGFs that can enter tissues. Additionally, about half of the circulating IGFBP-5 is found in ternary complexes with IGFs and an acid labile subunit; this high molecular complex cannot leave the circulation and acts as an IGF reservoir. IGFBPs 4-6 also have IGF-independent actions. These IGFBPs are regulated in a cell-specific manner and their dysregulation may play a role in a range of diseases including cancer. However, there is no clear clinical indication for measuring serum levels of these IGFBPs at present.
Collapse
Affiliation(s)
- Leon A Bach
- Department of Medicine (Alfred), Monash University, Prahran, 3181, Australia; Department of Endocrinology and Diabetes, Alfred Hospital, Melbourne, 3004, Australia.
| |
Collapse
|
15
|
Beattie J, Hawsawi Y, Alkharobi H, El-Gendy R. IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology. J Cell Commun Signal 2015; 9:151-8. [PMID: 25645979 DOI: 10.1007/s12079-015-0260-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 01/12/2015] [Indexed: 01/16/2023] Open
Abstract
The insulin-like growth factor (IGF) axis plays an important role in mammary gland physiology. In addition, dysregulation of this molecular axis may have a causal role in the aetiology and development of breast cancer (BC). This report discusses the IGF axis in normal and neoplastic mammary gland with special reference to IGF binding proteins (IGFBPs) -2 and -5. We describe how these high affinity binders of IGF-1 and IGF-2 may regulate local actions of growth factors in an autocrine and/or paracrine manner and how they also have IGF-independent effects in mammary gland. We discuss clinical studies which investigate both the prognostic value of IGFBP-2 and -5 expression in BC and possible involvement of these genes in the development of resistance to adjuvant endocrine therapies.
Collapse
Affiliation(s)
- James Beattie
- Department of Oral Biology, School of Dentistry, St James University Hospital, Level 7, Wellcome Trust Brenner Building, Leeds, LS9 7TF, UK,
| | | | | | | |
Collapse
|
16
|
Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage. J Cell Commun Signal 2015; 9:167-76. [PMID: 25617051 DOI: 10.1007/s12079-015-0262-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 01/12/2015] [Indexed: 10/24/2022] Open
Abstract
The complex mechanisms that cells have evolved to meet the challenge of constant exposure to DNA-damaging stimuli, also serve to protect cancer cells from the cytotoxic effects of chemo- and radiotherapy. IGFBPs appear to be involved, directly or indirectly, in some of these protective mechanisms. Activation of p53 is an early response to genotoxic stress, and all six human IGFBP genes have predicted p53 response elements in their promoter and/or intronic regions, at least some of which are functional. IGFBP3 has been extensively characterized as a p53-inducible gene, but in some cases it is suppressed by mutant p53 forms. DNA double-strand breaks (DSBs), induced by radiotherapy and some chemotherapies, potentially lead to apoptotic cell death, senescence, or repair and recovery. DSB damage can be repaired by homologous recombination or non-homologous end-joining (NHEJ), depending on the cell cycle stage, availability of key repair proteins, and other factors. The epidermal growth factor receptor (EGFR) has been implicated in the NHEJ pathway, and EGFR inhibition may inhibit repair, promoting apoptosis and thus improving sensitivity to chemotherapy or radiotherapy. Both IGFBP-3 and IGFBP-6 interact with components of the NHEJ pathway, and IGFBP-3 can facilitate this process through direct interaction with both EGFR and the catalytic subunit of DNA-PK. Cell fate after DNA damage may in part be regulated by the balance between the sphingolipids ceramide and sphingosine-1-phosphate, and IGFBPs can influence the production of both lipids. A better understanding of the involvement of IGFBPs in the DNA damage response in cancer cells may lead to improved methods of sensitizing cancers to DNA-damaging therapies.
Collapse
|
17
|
Zielinska HA, Bahl A, Holly JM, Perks CM. Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? BREAST CANCER-TARGETS AND THERAPY 2015; 7:9-19. [PMID: 25632238 PMCID: PMC4304531 DOI: 10.2147/bctt.s43932] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Evidence indicates that for most human cancers the problem is not that gene mutations occur but is more dependent upon how the body deals with damaged cells. It has been estimated that only about 1% of human cancers can be accounted for by unmistakable hereditary cancer syndromes, only up to 5% can be accounted for due to high-penetrance, single-gene mutations, and in total only 5%-15% of all cancers may have a major genetic component. The predominant contribution to the causation of most sporadic cancers is considered to be environmental factors contributing between 58% and 82% toward different cancers. A nutritionally poor lifestyle is associated with increased risk of many cancers, including those of the breast. As nutrition, energy balance, macronutrient composition of the diet, and physical activity levels are major determinants of insulin-like growth factor (IGF-I) bioactivity, it has been proposed that, at least in part, these increases in cancer risk and progression may be mediated by alterations in the IGF axis, related to nutritional lifestyle. Localized breast cancer is a manageable disease, and death from breast cancer predominantly occurs due to the development of metastatic disease as treatment becomes more complicated with poorer outcomes. In recent years, epithelial-to-mesenchymal transition has emerged as an important contributor to breast cancer progression and malignant transformation resulting in tumor cells with increased potential for migration and invasion. Furthermore, accumulating evidence suggests a strong link between components of the IGF pathway, epithelial-to-mesenchymal transition, and breast cancer mortality. Here, we highlight some recent studies highlighting the relationship between IGFs, IGF-binding protein 3, and epithelial-to-mesenchymal transition.
Collapse
Affiliation(s)
- Hanna A Zielinska
- IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK
| | - Amit Bahl
- Department of Clinical Oncology, Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, UK
| | - Jeff Mp Holly
- IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK
| | - Claire M Perks
- IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK
| |
Collapse
|
18
|
Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res 2014; 24:164-173. [PMID: 24953254 DOI: 10.1016/j.ghir.2014.04.007] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Accepted: 04/21/2014] [Indexed: 12/19/2022]
Abstract
One of the hallmarks in the advancement of cancer cells is an ability to overcome and acquire resistance to adverse conditions. There has been a large amount of cancer research on IGFBP-3 as a pro-apoptotic molecule in vitro. These pro-apoptotic properties, however, do not correlate with several studies linking high IGFBP-3 levels in breast cancer tissue to rapid growth and poor prognosis. Evidence is emerging that IGFBP-3 also exhibits pro-survival and growth-promoting properties in vitro. How IGFBP-3 pivots cell fate to either death or survival, it seems, comes down to a complex interplay between cells' microenvironments and the presence of cellular IGFBP-3 binding partners and growth factor receptors. The cytoprotective actions of IGFBP-3 are not restricted to cancer but are also observed in other disease states, such as retinopathy and brain ischaemia. Here we review the literature on this paradoxical nature of IGFBP-3, its pro-apoptotic and growth-inhibitory actions versus its cytoprotective and growth-potentiating properties, and discuss the implications of targeting IGFBP-3 for treatment of disease.
Collapse
Affiliation(s)
- Michael A Johnson
- Hormones and Cancer, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
| | - Sue M Firth
- Hormones and Cancer, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia
| |
Collapse
|
19
|
Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal·lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van’t Veer LJ, Th Rutgers EJ, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Zamora MP, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, TEO SH, YIP CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 2014; 4:4999. [PMID: 25248036 PMCID: PMC4321900 DOI: 10.1038/ncomms5999] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Accepted: 08/14/2014] [Indexed: 02/07/2023] Open
Abstract
GWAS have identified a breast cancer susceptibility locus on 2q35. Here we report the fine mapping of this locus using data from 101,943 subjects from 50 case-control studies. We genotype 276 SNPs using the 'iCOGS' genotyping array and impute genotypes for a further 1,284 using 1000 Genomes Project data. All but two, strongly correlated SNPs (rs4442975 G/T and rs6721996 G/A) are excluded as candidate causal variants at odds against >100:1. The best functional candidate, rs4442975, is associated with oestrogen receptor positive (ER+) disease with an odds ratio (OR) in Europeans of 0.85 (95% confidence interval=0.84-0.87; P=1.7 × 10(-43)) per t-allele. This SNP flanks a transcriptional enhancer that physically interacts with the promoter of IGFBP5 (encoding insulin-like growth factor-binding protein 5) and displays allele-specific gene expression, FOXA1 binding and chromatin looping. Evidence suggests that the g-allele confers increased breast cancer susceptibility through relative downregulation of IGFBP5, a gene with known roles in breast cell biology.
Collapse
Affiliation(s)
- Maya Ghoussaini
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Stacey L. Edwards
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Kyriaki Michailidou
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Silje Nord
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
| | - Richard Cowper-Sal·lari
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
| | - Kinjal Desai
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
- Geisel School of Medicine, Dartmouth College,
Hanover, New Hampshire
03755, USA
| | - Siddhartha Kar
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Kristine M. Hillman
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Susanne Kaufmann
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Dylan M. Glubb
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Jonathan Beesley
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Joe Dennis
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Manjeet K. Bolla
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Qin Wang
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Ed Dicks
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Qi Guo
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Marjanka K. Schmidt
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Mitul Shah
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Robert Luben
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Judith Brown
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Hatef Darabi
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Daniel Klevebring
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Stig E. Bojesen
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
- Faculty of Health and Medical Sciences, University of
Copenhagen, 2200
Copenhagen, Denmark
| | - Børge G. Nordestgaard
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
- Faculty of Health and Medical Sciences, University of
Copenhagen, 2200
Copenhagen, Denmark
| | - Sune F. Nielsen
- Copenhagen General Population Study, Herlev Hospital,
2730
Herlev, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, 2730
Herlev, Copenhagen, Denmark
| | - Henrik Flyger
- Department of Breast Surgery, Herlev Hospital, Copenhagen
University Hospital, 2730
Herlev, Copenhagen, Denmark
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Oncology,
University of Leuven, 3000
Leuven, Belgium
- Vesalius Research Center (VRC), VIB, 3000
Leuven, Belgium
| | - Bernard Thienpont
- Vesalius Research Center (VRC), VIB, 3000
Leuven, Belgium
- Vesalius Research Center, University of Leuven,
3000
Leuven, Belgium
| | - Patrick Neven
- Department of Oncology, University of Leuven,
3000
Leuven, Belgium
- Multidisciplinary Breast Center, Department of General Medical
Oncology, University Hospitals Leuven, 3000
Leuven, Belgium
| | - Hans Wildiers
- Department of Oncology, University of Leuven,
3000
Leuven, Belgium
- Multidisciplinary Breast Center, Department of General Medical
Oncology, University Hospitals Leuven, 3000
Leuven, Belgium
| | - Annegien Broeks
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Laura J. Van’t Veer
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Emiel J. Th Rutgers
- Netherlands Cancer Institute, Antoni van Leeuwenhoek
hospital, 1066 CX
Amsterdam, The Netherlands
| | - Fergus J. Couch
- Department of Laboratory Medicine and Pathology, Mayo
Clinic, Rochester, Minnesota
55905, USA
| | - Janet E. Olson
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Emily Hallberg
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Celine Vachon
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Anja Rudolph
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Petra Seibold
- Division of Cancer Epidemiology, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Dieter Flesch-Janys
- Department of Cancer Epidemiology/Clinical Cancer Registry and
Institute for Medical Biometrics and Epidemiology, University Clinic
Hamburg-Eppendorf, 20246
Hamburg, Germany
| | - Julian Peto
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Isabel dos-Santos-Silva
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Lorna Gibson
- Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University
Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Taru A. Muranen
- Department of Obstetrics and Gynecology, Helsinki University
Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Kristiina Aittomäki
- Department of Clinical Genetics, University of Helsinki,
Helsinki University Central Hospital, Helsinki,
FI-00029
HUS, Finland
| | - Carl Blomqvist
- Department of Oncology, University of Helsinki, Helsinki
University Central Hospital, Helsinki, FI-00029
HUS, Finland
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Jingmei Li
- Human Genetics Division, Genome Institute of Singapore,
Singapore
138672, Singapore
| | - Jianjun Liu
- Human Genetics Division, Genome Institute of Singapore,
Singapore
138672, Singapore
| | - Keith Humphreys
- Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Daehee Kang
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
- Department of Preventive Medicine, Seoul National University
College of Medicine, Seoul
110-799, Korea
| | - Ji-Yeob Choi
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
| | - Sue K. Park
- Cancer Research Institute, Seoul National University College of
Medicine, Seoul
110-799, Korea
- Department of Biomedical Sciences, Seoul National University
Graduate School, Seoul
151-742, Korea
- Department of Preventive Medicine, Seoul National University
College of Medicine, Seoul
110-799, Korea
| | - Dong-Young Noh
- Department of Surgery, Seoul National University College of
Medicine, Seoul
110-799, Korea
| | - Keitaro Matsuo
- Department of Preventive Medicine, Kyushu University Faculty of
Medical Sciences, Fukuoka
812-8582, Japan
| | - Hidemi Ito
- Division of Epidemiology and Prevention, Aichi Cancer Center
Research Institute, Nagoya, Aichi
464-8681, Japan
| | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center
Hospital, Nagoya
484-8681, Japan
| | - Yasushi Yatabe
- Department of Pathology and Molecular Diagnostics, Aichi Cancer
Center Hospital, Nagoya
484-8681, Japan
| | - Pascal Guénel
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Thérèse Truong
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Florence Menegaux
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Marie Sanchez
- Inserm (National Institute of Health and Medical Research),
CESP (Center for Research in Epidemiology and Population Health), U1018,
Environmental Epidemiology of Cancer, 94807
Villejuif, France
- University Paris-Sud, UMRS 1018, 94807
Villejuif, France
| | - Barbara Burwinkel
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- Molecular Epidemiology Group, German Cancer Research Center
(DKFZ), 69120
Heidelberg, Germany
| | - Frederik Marme
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- National Center for Tumor Diseases, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Andreas Schneeweiss
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
- National Center for Tumor Diseases, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Christof Sohn
- Department of Obstetrics and Gynecology, University of
Heidelberg, 69120
Heidelberg, Germany
| | - Anna H. Wu
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Chiu-chen Tseng
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - David Van Den Berg
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Daniel O. Stram
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California, Los Angeles,
California
90033, USA
| | - Javier Benitez
- Centro de Investigación en Red de Enfermedades Raras
(CIBERER), 46010
Valencia, Spain
- Human Genetics Group, Human Cancer Genetics Program, Spanish
National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - M. Pilar Zamora
- Servicio de Oncología Médica, Hospital
Universitario La Paz, 28046
Madrid, Spain
| | | | - Primitiva Menéndez
- Servicio de Anatomía Patológica, Hospital
Monte Naranco, 33013
Oviedo, Spain
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Wei Lu
- Shanghai Center for Disease Control and Prevention,
Shanghai
200336, China
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Cancer Institute,
Shanghai
200032, China
| | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Angela Cox
- CRUK/YCR Sheffield Cancer Research Centre, Department of
Oncology, University of Sheffield, Sheffield
S10 2RX, UK
| | - Simon S. Cross
- Academic Unit of Pathology, Department of Neuroscience,
University of Sheffield, Sheffield
S10 2HQ, UK
| | - Malcolm W. R. Reed
- CRUK/YCR Sheffield Cancer Research Centre, Department of
Oncology, University of Sheffield, Sheffield
S10 2RX, UK
| | - Irene L. Andrulis
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada
M5G 1X5
- Department of Molecular Genetics, University of Toronto,
Toronto, Ontario, Canada
M5S 1A8
| | - Julia A. Knight
- Division of Epidemiology, Dalla Lana School of Public Health,
University of Toronto, Toronto, Ontario,
Canada
M5T 3M7
- Prosserman Centre for Health Research, Lunenfeld-Tanenbaum
Research Institute of Mount Sinai Hospital, Toronto,
Ontario, Canada
M5G 1X5
| | - Gord Glendon
- Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research
Institute of Mount Sinai Hospital, Toronto, Ontario,
Canada
M5G 1X5
| | - Sandrine Tchatchou
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, Ontario, Canada
M5G 1X5
| | - Elinor J. Sawyer
- Division of Cancer Studies, NIHR Comprehensive Biomedical
Research Centre, Guy’s & St Thomas’ NHS Foundation
Trust in partnership with King's College London, London
SE1 9RT, UK
| | - Ian Tomlinson
- Wellcome Trust Centre for Human Genetics, Oxford Biomedical
Research Centre, University of Oxford, Oxford
OX3 7BN, UK
| | - Michael J. Kerin
- Clinical Science Institute, University Hospital Galway,
Galway, Ireland
| | - Nicola Miller
- Clinical Science Institute, University Hospital Galway,
Galway, Ireland
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Fredrick Schumacher
- Department of Preventive Medicine, Keck School of Medicine,
University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, California
90033, USA
| | - Loic Le Marchand
- Epidemiology Program, Cancer Research Center, University of
Hawaii, Honolulu, Hawaii
96813, USA
| | - Annika Lindblom
- Department of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Sara Margolin
- Department of Oncology—Pathology, Karolinska
Institutet, Stockholm
SE-17177, Sweden
| | - Soo Hwang TEO
- Breast Cancer Research Unit, University Malaya Cancer Research
Institute, University Malaya Medical Centre, 59100
Kuala Lumpur, Malaysia
- Cancer Research Initiatives Foundation, Sime Darby Medical
Centre, Subang Jaya
47500
Selangor, Malaysia
| | - Cheng Har YIP
- Breast Cancer Research Unit, University Malaya Cancer Research
Institute, University Malaya Medical Centre, 59100
Kuala Lumpur, Malaysia
| | - Daphne S. C. Lee
- Cancer Research Initiatives Foundation, Sime Darby Medical
Centre, Subang Jaya
47500
Selangor, Malaysia
| | - Tien Y. Wong
- Singapore Eye Research Institute, National University of
Singapore, Singapore
168751, Singapore
| | - Maartje J. Hooning
- Department of Medical Oncology, Erasmus MC Cancer
Institute, 3008 AE
Rotterdam, The Netherlands
| | - John W. M. Martens
- Department of Medical Oncology, Erasmus MC Cancer
Institute, 3008 AE
Rotterdam, The Netherlands
| | - J. Margriet Collée
- Department of Clinical Genetics, Erasmus University Medical
Center, 3000 CA
Rotterdam, The Netherlands
| | | | - John L. Hopper
- Centre for Molecular, Environmental, Genetic and Analytical
Epidemiology, Melbourne School of Population Health, University of
Melbourne, Melbourne, Victoria
3010, Australia
| | - Melissa C. Southey
- Department of Pathology, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Helen Tsimiklis
- Department of Pathology, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Miroslav K. Kapuscinski
- Centre for Molecular, Environmental, Genetic and Analytical
Epidemiology, Melbourne School of Population Health, University of
Melbourne, Melbourne, Victoria
3010, Australia
| | - Chen-Yang Shen
- College of Public Health, China Medical University,
Taichung
40402, Taiwan, China
- Institute of Biomedical Sciences, Academia Sinica,
Taipei
115, Taiwan, China
| | - Pei-Ei Wu
- Taiwan Biobank, Institute of Biomedical Sciences, Academia
Sinica, Taipei
115, Taiwan, China
| | - Jyh-Cherng Yu
- Department of Surgery, Tri-Service General Hospital,
Taipei
114, Taiwan, China
| | - Shou-Tung Chen
- Department of Surgery, Changhua Christian Hospital,
Changhua City
500, Taiwan, China
| | - Grethe Grenaker Alnæs
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
| | - Anne-Lise Borresen-Dale
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
- Institute of Clinical Medicine, University of Oslo (UiO),
0318
Oslo, Norway
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria,
Melbourne, Victoria
3004, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne,
Melbourne, Victoria
3010, Australia
| | - Roger L. Milne
- Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne,
Melbourne, Victoria
3010, Australia
- Cancer Epidemiology Centre, The Cancer Council Victoria,
Melbourne, Victoria
3053, Australia
| | - Catriona McLean
- Anatomical Pathology, The Alfred Hospital,
Melbourne, Victoria
3004, Australia
| | - Kenneth Muir
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
- Institute of Population Health, University of Manchester,
Manchester
M13 9PL, UK
| | - Artitaya Lophatananon
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
| | - Sarah Stewart-Brown
- Division of Health Sciences, Warwick Medical School, Warwick
University, Coventry
CV4 7AL, UK
| | | | - Mikael Hartman
- Department of Surgery, Yong Loo Lin School of Medicine,
National University of Singapore and National University Health System,
Singapore
119228, Singapore
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
| | - Hui Miao
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
| | | | - Yik Ying Teo
- Saw Swee Hock School of Public Health, National University of
Singapore and National University Health System, Singapore
117597, Singapore
- Department of Statistics and Applied Probability, National
University of Singapore, Singapore
117546, Singapore
| | - Peter A. Fasching
- Division of Hematology and Oncology, Department of Medicine,
David Geffen School of Medicine, University of California at Los Angeles,
Los Angeles, California
90095, USA
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Lothar Haeberle
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Arif B. Ekici
- Institute of Human Genetics, University Hospital Erlangen,
Friedrich Alexander University Erlangen-Nuremberg, 91054
Erlangen, Germany
| | - Matthias W. Beckmann
- Department of Gynecology and Obstetrics, University Breast
Center Franconia, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
91054
Erlangen, Germany
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
- German Cancer Consortium (DKTK), 69120
Heidelberg, Germany
| | - Aida Karina Dieffenbach
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
- German Cancer Consortium (DKTK), 69120
Heidelberg, Germany
| | - Volker Arndt
- Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), 69120
Heidelberg, Germany
| | | | - Anthony Swerdlow
- Division of Breast Cancer Research, Institute of Cancer
Research, London
SM2 5NG, UK
- Division of Genetics and Epidemiology, Institute of Cancer
Research, London
SM2 5NG, UK
| | - Alan Ashworth
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
| | - Nick Orr
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
| | - Minouk J. Schoemaker
- Division of Genetics and Epidemiology, Institute of Cancer
Research, London
SM2 5NG, UK
| | - Montserrat García-Closas
- Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London
SW3 6JB, UK
- Division of Genetics and Epidemiology, Institute of Cancer
Research, Sutton, Surrey
SM2 5NG, UK
| | - Jonine Figueroa
- Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, Maryland
20850, USA
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, Maryland
20850, USA
| | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M.
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
02-781
Warsaw, Poland
| | - Jacques Simard
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire
de Québec Research Center, Laval University, Quebec,
Canada
G1V 4G2
| | - Mark S. Goldberg
- Department of Medicine, McGill University,
Montreal, Quebec, Canada
H3G 2M1
- Division of Clinical Epidemiology, McGill University Health
Centre, Royal Victoria Hospital, Montreal, Quebec,
Canada
H3A 1A8
| | - France Labrèche
- Département de médecine sociale et
préventive, Département de santé environnementale et
santé au travail, Université de Montréal,
Montreal, Quebec, Canada
H3T 1A8
| | - Martine Dumont
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire
de Québec Research Center, Laval University, Quebec,
Canada
G1V 4G2
| | - Robert Winqvist
- Laboratory of Cancer Genetics and Tumor Biology, Department of
Clinical Chemistry and Biocenter Oulu, NordLab Oulu/Oulu University Hospital,
University of Oulu, FI-90220
Oulu, Finland
| | - Katri Pylkäs
- Laboratory of Cancer Genetics and Tumor Biology, Department of
Clinical Chemistry and Biocenter Oulu, NordLab Oulu/Oulu University Hospital,
University of Oulu, FI-90220
Oulu, Finland
| | - Arja Jukkola-Vuorinen
- Department of Oncology, Oulu University Hospital, University
of Oulu, FI-90220
Oulu, Finland
| | - Hiltrud Brauch
- Dr Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, 70376
Stuttgart, Germany
- University of Tübingen, 72074
Tübingen, Germany
- German Cancer Consortium (DKTK) and German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
| | - Thomas Brüning
- Institute for Prevention and Occupational Medicine of the
German Social Accident Insurance, Institute of the Ruhr University Bochum
(IPA), 44789
Bochum, Germany
| | - Yon-Dschun Koto
- Department of Internal Medicine, Evangelische Kliniken Bonn
gGmbH, Johanniter Krankenhaus, 53113
Bonn, Germany
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing,
Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto
Nazionale dei Tumori (INT), 20133
Milan, Italy
| | - Paolo Peterlongo
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare,
20139
Milan, Italy
| | - Bernardo Bonanni
- Division of Cancer Prevention and Genetics, Istituto Europeo
di Oncologia (IEO), 20141
Milan, Italy
| | - Sara Volorio
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare,
20139
Milan, Italy
- Cogentech Cancer Genetic Test Laboratory,
20133
Milan, Italy
| | - Thilo Dörk
- Department of Obstetrics and Gynaecology, Hannover Medical
School, 30625
Hannover, Germany
| | - Natalia V. Bogdanova
- Department of Radiation Oncology, Hannover Medical
School, 30625
Hannover, Germany
| | - Sonja Helbig
- Department of Obstetrics and Gynaecology, Hannover Medical
School, 30625
Hannover, Germany
| | - Arto Mannermaa
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Vesa Kataja
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Veli-Matti Kosma
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Jaana M. Hartikainen
- Cancer Center of Eastern Finland, University of Eastern
Finland, FI-70211
Kuopio, Finland
- Imaging Center, Department of Clinical Pathology, Kuopio
University Hospital, FI-70210
Kuopio, Finland
- School of Medicine, Institute of Clinical Medicine, Oncology,
University of Eastern Finland, FI-70211
Kuopio, Finland
| | - Peter Devilee
- Department of Human Genetics & Department of
Pathology, Leiden University Medical Center, 2300 RC
Leiden, The Netherlands
| | | | - Caroline Seynaeve
- Family Cancer Clinic, Department of Medical Oncology, Erasmus
MC-Daniel den Hoed Cancer Centre, 3075 EA
Rotterdam, The Netherlands
| | - Christi J. Van Asperen
- Department of Clinical Genetics, Erasmus University Medical
Center, 3000 CA
Rotterdam, The Netherlands
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | | | - Katarzyna Durda
- Department of Genetics and Pathology, Pomeranian Medical
University, 70-115
Szczecin, Poland
| | - Susan Slager
- Department of Health Sciences Research, Mayo Clinic,
Rochester, Minnesota
55905, USA
| | - Amanda E. Toland
- Department of Molecular Virology, Immunology and Medical
Genetics, Comprehensive Cancer Center, The Ohio State University,
Columbus, Ohio
43210, USA
| | | | - Drakoulis Yannoukakos
- Molecular Diagnostics Laboratory, IRRP, National Centre for
Scientific Research ‘Demokritos’, Aghia Paraskevi
Attikis, Athens
15310, Greece
| | | | | | - Paul Brennan
- International Agency for Research on Cancer,
Lyon, Cedex 08, France
| | - James McKay
- International Agency for Research on Cancer,
Lyon, Cedex 08, France
| | - Ute Hamann
- Molecular Genetics of Breast Cancer, German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
| | - Diana Torres
- Molecular Genetics of Breast Cancer, German Cancer Research
Center (DKFZ), 69120
Heidelberg, Germany
- Institute of Human Genetics, Pontificia University
Javeriana, Bogota, DC
11001000, Colombia
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Jirong Long
- Division of Epidemiology, Department of Medicine, Vanderbilt
Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University
School of Medicine, Nashville, Tennessee
37203, USA
| | - Hoda Anton-Culver
- Department of Epidemiology, University of California
Irvine, Irvine, California
92697, USA
| | - Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute
of City of Hope, Duarte, California
92697, USA
| | - Craig Luccarini
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Caroline Baynes
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Shahana Ahmed
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Mel Maranian
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Catherine S. Healey
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| | - Anna González-Neira
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Guillermo Pita
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - M. Rosario Alonso
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Nuria Álvarez
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Daniel Herrero
- Human Genotyping-CEGEN Unit, Human Cancer Genetics Program,
Spanish National Cancer Research Centre (CNIO), 28029
Madrid, Spain
| | - Daniel C. Tessier
- Centre d’innovation Génome Québec
et Université McGill, Montréal,
Quebec, Canada
H3A OG1
| | | | | | - Ines de Santiago
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Jason Carroll
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Carlos Caldas
- Cancer Research UK, Cambridge Institute, University of
Cambridge, Robinson Way, Cambridge
CB2 0RE, UK
| | - Melissa A. Brown
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Mathieu Lupien
- The Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada
M5T 2M9
- Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research
Institute of Mount Sinai Hospital, Toronto, Ontario,
Canada
M5G 1X5
- Department of Medical Biophysics, University of Toronto,
Toronto, Ontario, Canada
M5G 1L7
| | - Vessela N. Kristensen
- Department of Genetics, Institute for Cancer Research, Oslo
University Hospital, Radiumhospitalet, N-0310
Oslo, Norway
- Institute of Clinical Medicine, University of Oslo (UiO),
0318
Oslo, Norway
- Department of Clinical Molecular Biology (EpiGen), University
of Oslo (UiO), 0450
Oslo, Norway
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Georgia Chenevix-Trench
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
| | - Juliet D French
- Department of Genetics, QIMR Berghofer Medical Research
Institute, Brisbane, Queensland
4029, Australia
- School of Chemistry and Molecular Biosciences, The University of
Queensland, Brisbane, Queensland
4072, Australia
| | - Douglas F. Easton
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
- Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Cambridge
CB1 8RN, UK
| | - Alison M. Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge
CB1 8RN, UK
| |
Collapse
|
20
|
Abstract
The six members of the family of insulin-like growth factor (IGF) binding proteins (IGFBPs) were originally characterized as passive reservoirs of circulating IGFs, but they are now understood to have many actions beyond their endocrine role in IGF transport. IGFBPs also function in the pericellular and intracellular compartments to regulate cell growth and survival - they interact with many proteins, in addition to their canonical ligands IGF-I and IGF-II. Intranuclear roles of IGFBPs in transcriptional regulation, induction of apoptosis and DNA damage repair point to their intimate involvement in tumour development, progression and resistance to treatment. Tissue or circulating IGFBPs might also be useful as prognostic biomarkers.
Collapse
Affiliation(s)
- Robert C Baxter
- Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
| |
Collapse
|
21
|
Batarseh G, Windsor LJ, Labban NY, Liu Y, Gregson K. Triethylene Glycol Dimethacrylate Induction of Apoptotic Proteins in Pulp Fibroblasts. Oper Dent 2014; 39:E1-8. [DOI: 10.2341/12-417-l] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
SUMMARY
Objective
Monomers such as triethylene glycol dimethacrylate (TEGDMA) can leach from dental composites. TEGDMA-induced apoptosis in human pulp has been reported. However, the apoptotic (pro or anti) proteins involved in this process remain unclear. Therefore, the purpose of this study was to determine which apoptotic proteins are enhanced or suppressed during TEGDMA-induced apoptosis.
Materials and Methods
Human pulp fibroblasts (HPFs) were incubated with different TEGDMA concentrations (0.125-1.0 mM) and cytotoxicity was determined. TEGDMA was shown to be cell cytotoxic at concentrations of 0.50 mM and higher. The highest concentration with no significant cytotoxicity was then incubated (0.25 mM TEGDMA) with the HPFs. Cell lysates were then prepared and the protein concentrations determined. Human Apoptosis Array kits were utilized to detect the relative levels of 43 apoptotic proteins.
Results
HPFs exposed to TEGDMA showed significant increases in multiple pro-apoptotic proteins such as Bid, Bim, Caspase 3, Caspase 8, and Cytochrome c at 24 hours. Some anti-apoptotic proteins were also altered.
Conclusions
The results indicated that TEGDMA activates both the extrinsic and intrinsic apoptotic pathways.
Collapse
Affiliation(s)
- G Batarseh
- Ghada Batarseh, DDS, MSD, Department of Oral Biology, Indiana University-Purdue University–Indianapolis, Indianapolis, IN, USA
| | - LJ Windsor
- L Jack Windsor, PhD, Department of Oral Biology, Indiana University-Purdue University–Indianapolis, Indianapolis, IN, USA
| | - NY Labban
- Nawaf Y Labban, BDS, MSD, Department of Oral Biology, Indiana University School of Dentistry, Indianapolis, IN, USA and Department of Prosthetic Dental Science, King Saud University College of Dentistry, Riyadh, KSA
| | - Y Liu
- Yang Liu, Sichuan University, State Key Laboratory of Oral Diseases, Chengdu, China
| | - K Gregson
- Karen Gregson, Indiana University, Indianapolis, IN, USA
| |
Collapse
|
22
|
Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther 2013; 13:316-28. [PMID: 24337110 DOI: 10.1158/1535-7163.mct-13-0367] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The type I EGF receptor (EGFR or ErbB1) and insulin-like growth factor-binding protein-3 (IGFBP-3) are highly expressed in triple-negative breast cancer (TNBC), a particularly aggressive disease that cannot be treated with conventional therapies targeting the estrogen or progesterone receptors (ER and PR), or HER2. We have shown previously in normal breast epithelial cells that IGFBP-3 potentiates growth-stimulatory signaling transduced by EGFR, and this is mediated by the sphingosine kinase-1 (SphK1)/sphingosine 1-phosphate (S1P) system. In this study, we investigated whether cotargeting the EGFR and SphK1/S1P pathways in TNBC cells results in greater growth inhibition compared with blocking either alone, and might therefore have novel therapeutic potential in TNBC. In four TNBC cell lines, exogenous IGFBP-3 enhanced ligand-stimulated EGFR activation, associated with increased SphK1 localization to the plasma membrane. The effect of exogenous IGFBP-3 on EGFR activation was blocked by pharmacologic inhibition or siRNA-mediated silencing of SphK1, and silencing of endogenous IGFBP-3 also suppressed EGF-stimulated EGFR activation. Real-time analysis of cell proliferation revealed a combined effect of EGFR inhibition by gefitinib and SphK1 inhibition using SKi-II. Growth of MDA-MB-468 xenograft tumors in mice was significantly inhibited by SKi-II and gefitinib when used in combination, but not as single agents. We conclude that IGFBP-3 promotes growth of TNBC cells by increasing EGFR signaling, that this is mediated by SphK1, and that combined inhibition of EGFR and SphK1 has potential as an anticancer therapy in TNBC in which EGFR and IGFBP-3 expression is high.
Collapse
Affiliation(s)
- Janet L Martin
- Corresponding Author: Janet L. Martin, Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia.
| | | | | | | | | |
Collapse
|
23
|
Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta Rev Cancer 2013; 1836:345-53. [PMID: 24189571 DOI: 10.1016/j.bbcan.2013.10.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 10/15/2013] [Accepted: 10/24/2013] [Indexed: 12/22/2022]
Abstract
Development and differentiation of the mammary gland are dependent on the appropriate temporal expression of both systemically acting hormones and locally produced growth factors. A large body of evidence suggests that molecular crosstalk between these hormonal and growth factor axes is crucial for appropriate cell and tissue function. Two of the most important trophic factors involved in this process are the oestrogen (E) and insulin-like growth factor (IGF) molecular axes. The reciprocal crosstalk that exists between these pathways occurs at transcriptional/post-transcriptional and translational/post-translational levels regulate the expression and activity of genes involved in this process. In a clinical context an important consequence of such crosstalk in the mammary gland is the role which it may play in the aetiology, maintenance and development of breast tumours. Although oestradiol (E2) acting through oestrogen receptors α and β (ERα/β) is important for normal mammary gland function it can also provide a mitogenic drive to ER+ breast tumours. Therefore over several years anti-oestrogen therapeutic regimens in the form of selective oestrogen receptor modulators (SERMs - e.g. tamoxifen), aromatase inhibitors (AI e.g. anastrozole) or selective oestrogen receptor down regulators (SERDs - e.g. fulvestrant) have been used in an adjuvant setting to control tumour growth. Although initial response is usually encouraging, large cohorts of patients eventually develop resistance to these treatments leading to tumour recurrence and poor prognosis. There are potentially many routes by which breast cancer (BC) cells could escape anti-oestrogen based therapeutic strategies and one of the most studied is the possible growth factor mediated activation of ER(s). Because of this, growth factor modulation of ER activity has been an intensively studied route of molecular crosstalk in the mammary gland. The insulin-like growth factors (IGF-1 and -2) are amongst the most potent mitogens for mammary epithelial cells and there is accumulating evidence that they interact with the E2 axis to regulate mitogenesis, apoptosis, adhesion, migration and differentiation of mammary epithelial cells. Such interactions are bi-directional and E2 has been shown to regulate the expression and activity of IGF axis genes with the general effect of sensitising breast epithelial cells to the actions of IGFs and insulin. In this short review we discuss the evidence for the involvement of crosstalk between the insulin-like growth factor (IGF) and oestrogen axes in the mammary gland and comment on the relevance of such studies in the aetiology and treatment of BC.
Collapse
|
24
|
Perks CM, Burrows C, Holly JMP. Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide. Front Endocrinol (Lausanne) 2011; 2:13. [PMID: 22654794 PMCID: PMC3356103 DOI: 10.3389/fendo.2011.00013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Accepted: 05/03/2011] [Indexed: 11/29/2022] Open
Abstract
We established previously that IGFBP-3 could exert positive or negative effects on cell function depending upon the extracellular matrix composition and by interacting with integrin signaling. To elicit its pro-apoptotic effects IGFBP-3 bound to caveolin-1 and the beta 1 integrin receptor and increased their association culminating in MAPK activation. Disruption of these complexes or blocking the beta 1 integrin receptor reversed these intrinsic actions of IGFBP-3. In this study we have examined the signaling pathway between integrin receptor binding and MAPK activation that mediates the intrinsic, pro-apoptotic actions of IGFBP-3. We found on inhibiting protein kinase A (PKA), Rho associated kinase (ROCK), and ceramide, the accentuating effects of IGFBP-3 on apoptotic triggers were reversed, such that IGFBP-3 then conferred cell survival. We established that IGFBP-3 activated Rho, the upstream regulator of ROCK and that beta1 integrin and PKA were upstream of Rho activation, whereas the involvement of ceramide was downstream. The beta 1 integrin, PKA, Rho, and ceramide were all upstream of MAPK activation. These data highlight key components involved in the pro-apoptotic effects of IGFBP-3 and that inhibiting them leads to a reversal in the action of IGFBP-3.
Collapse
Affiliation(s)
- Claire M. Perks
- *Correspondence: Claire M. Perks, IGF and Metabolic Endocrinology Group, Department of Clinical Sciences at North Bristol, The Medical School, Southmead Hospital, University of Bristol, Bristol, BS10 5NB, UK. e-mail:
| | - Carla Burrows
- IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, Learning and Research Building, Southmead Hospital, University of BristolBristol, UK
| | - Jeff M. P. Holly
- IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, Learning and Research Building, Southmead Hospital, University of BristolBristol, UK
| |
Collapse
|
25
|
Worthmann K, Peters I, Kümpers P, Saleem M, Becker JU, Agustian PA, Achenbach J, Haller H, Schiffer M. Urinary excretion of IGFBP-1 and -3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease. Growth Factors 2010; 28:129-38. [PMID: 20102313 DOI: 10.3109/08977190903512594] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The glomerular microenvironment is influenced by circulating growth factors that are filtered from the blood stream and pass the glomerular filtration barrier. In this study, we wanted to explore the role of IGF-binding proteins (IGFBPs) in two diseases that concern podocytes. We analyzed glomerular expression and urinary excretion of IGFBP-1, -2, and -3 in patients with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). We found that patients with active FSGS excrete high amounts of podocalyxin positive cells as well as IGFBP-1 and -3. In human podocytes, we can induce mRNA expression of IGFBP-3 in response to TGF-beta and in human microvascular endothelial cells expression of IGFBP-1 and -3 in response to TGF-beta and Bradykinin. We conclude that the local expression of IGFBPs in podocytes and endothelial cells might contribute to the pathogenesis of glomerular disease and that IGFBP-1 and -3 are potential non-invasive markers of FSGS.
Collapse
Affiliation(s)
- Kirstin Worthmann
- Department of Medicine/Nephrology, Hannover Medical School, Carl Neuberg Street 1, Hannover, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ahn BY, Elwi AN, Lee B, Trinh DLN, Klimowicz AC, Yau A, Chan JA, Magliocco A, Kim SW. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 2010; 70:3013-9. [PMID: 20354179 DOI: 10.1158/0008-5472.can-09-3108] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tamoxifen resistance is one of the overarching challenges in the treatment of patients with estrogen receptor (ER)-positive breast cancer. Through a genome-wide RNA interference screen to discover genes responsible for tamoxifen resistance in vitro, we identified insulin-like growth factor binding protein 5 (IGFBP5) as a determinant of drug sensitivity. Specific knockdown of IGFBP5 by retroviral infection with short hairpin RNA-expressing cassette in MCF7 human breast cancer cells (pRS-shIGFBP5) conferred tamoxifen resistance in vitro due to concomitant loss of ERalpha expression and signaling. IGFBP5 expression was also reduced in MCF7 cells selected for tamoxifen resistance in culture (TAMR). Both tamoxifen-resistant MCF7-TAMR and MCF7-pRS-shIGFBP5 cells could be resensitized to drug by treatment with exogenous recombinant IGFBP5 (rIGFBP5) protein. Treatment with rIGFBP5 protein in mouse tumor xenografts reversed the in vivo tamoxifen resistance of MCF7-pRS-shIGFBP5 cell-derived tumors by reducing tumor cell proliferation. IGFBP5 immunohistochemical staining in a cohort of 153 breast cancer patients showed that low IGFBP5 expression was associated with shorter overall survival after tamoxifen therapy. Thus, IGFBP5 warrants investigation as an agent to reverse tamoxifen resistance.
Collapse
Affiliation(s)
- Bo Young Ahn
- Department of Biochemistry and Molecular Biology, Laboratory Medicine, Clark H Smith Brain Tumour Centre, and Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. FIBROGENESIS & TISSUE REPAIR 2010; 3:3. [PMID: 20163708 PMCID: PMC2834615 DOI: 10.1186/1755-1536-3-3] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Accepted: 02/17/2010] [Indexed: 02/06/2023]
Abstract
Background Expression of insulin-like growth factor binding protein 5 (IGFBP5) is strongly induced upon activation of hepatic stellate cells and their transdifferentiation into myofibroblasts in vitro. This was confirmed in vivo in an animal model of liver fibrosis. Since IGFBP5 has been shown to promote fibrosis in other tissues, the aim of this study was to investigate its role in the progression of liver fibrosis. Methods The effect of IGFBP5 was studied in LX2 cells, a model for partially activated hepatic stellate cells, and in human primary liver myofibroblasts. IGFBP5 signalling was modulated by the addition of recombinant protein, by lentiviral overexpression, and by siRNA mediated silencing. Furthermore, the addition of IGF1 and silencing of the IGF1R was used to investigate the role of the IGF-axis in IGFBP5 mediated effects. Results IGFBP5 enhanced the survival of LX2 cells and myofibroblasts via a >50% suppression of apoptosis. This effect of IGFBP5 was not modulated by the addition of IGF1, nor by silencing of the IGF1R. Additionally, IGFBP5 was able to enhance the expression of established pro-fibrotic markers, such as collagen Iα1, TIMP1 and MMP1. Conclusion IGFBP5 enhances the survival of (partially) activated hepatic stellate cells and myofibroblasts by lowering apoptosis via an IGF1-independent mechanism, and enhances the expression of profibrotic genes. Its lowered expression may, therefore, reduce the progression of liver fibrosis.
Collapse
|
28
|
Steiger-Luther NC, Darwiche H, Oh SH, Williams JM, Petersen BE. Insulin-like growth factor binding protein-3 is required for the regulation of rat oval cell proliferation and differentiation in the 2AAF/PHX model. Hepat Med 2010; 2010:13-32. [PMID: 21852899 PMCID: PMC3156464 DOI: 10.2147/hmer.s7660] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Oval cell-mediated liver regeneration is a highly complex process that involves the coordination of several signaling factors, chemokines and cytokines to allow for proper maintenance of the liver architecture. When hepatocyte proliferation is inhibited, an hepatic stem cell population, often referred to as “oval cells”, is activated to aid in liver regeneration. The function of insulin-like growth factor binding protein-3 (IGFBP-3) during this process of oval cell activation is of particular interest because it is produced in liver and has been shown to induce migration and differentiation of other stem cell populations both in vitro and in vivo. Additionally, IGFBP-3 production has been linked to the transforming growth factor-β (TGF-β) superfamily, a pathway known to be induced during oval cell proliferation. In this study, we set out to determine whether IGFBP-3 plays a role in oval cell proliferation, migration and differentiation during this specific type of regeneration. Through activation of the oval cell-mediated liver regeneration in a rat model, we found that IGFBP-3 is elevated in the liver and serum of animals during peak days of oval cell activation and proliferation. Furthermore, in vitro assays found that WB-344 cells, a liver stem cell line similar to oval cells, were induced to migrate in the presence of IGFBP-3. When expression of IGFBP-3 was knocked down during oval cell activation in vivo, we found that oval cell proliferation was increased and observed the appearance of numerous atypical ductular structures, which were OV-6 and Ki67-positive. Finally, quantitative realtime PCR analysis of liver tissue from IGFBP-3 small interfering RNA (siRNA) treated animals determined that expression of TGFβ family members, including TGF-βRII and Smads 2–4, were significantly downregulated compared to animals at day 9 post-PHx alone or animals that received negative control siRNA. In conclusion, IGFBP-3 may function as a potent chemoattractant of oval cells during specific types of liver regeneration and may be involved in regulating oval cell proliferation and differentiation in vivo via the TGF-β pathway.
Collapse
Affiliation(s)
- Nicole C Steiger-Luther
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA
| | | | | | | | | |
Collapse
|
29
|
Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA. Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer 2010; 126:350-61. [PMID: 19588500 DOI: 10.1002/ijc.24727] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The insulin like growth factor (IGF) signaling pathway has been shown to contribute to melanoma progression, but little is known about the role of the IGF binding protein 3 (IGFBP-3) in melanoma biology. The aim of the present study was to characterize expression, function and regulation of IGFBP-3 in malignant melanomas and study its potential as a biomarker. The expression of IGFBP-3 varied between different human melanoma cell lines and reintroduction of the protein in non-expressing cells led to induction of apoptosis. Interestingly, in cell lines expressing endogenous IGFBP-3, siRNA silencing of the protein led to a cell line-dependent decrease in proliferation, but had no effect on apoptosis and invasion. Examination of patient material showed that IGFBP-3 is unexpressed in benign nevi while a slight increase in protein expression was seen in primary and metastatic melanoma. However, expression of the protein was low and no correlation was found with circulating levels of IGFBP-3 in serum, suggesting that IGFBP-3 has limited potential as a predictive marker in malignant melanoma. We showed that promoter methylation of IGFBP-3 occurred in both melanoma cell lines and patient material, implicating epigenetic silencing as a regulation mechanism. Furthermore, expression of the protein was shown to be regulated by the PI3-kinase/AKT and MAPK/ERK1/2 pathways. In summary, our findings suggest that IGFBP-3 can exert dual functional effects influencing both apoptosis and proliferation. Development of resistance to the antiproliferative effects of IGFBP-3 may be an important step in progression of malignant melanomas.
Collapse
Affiliation(s)
- Geir Frode Oy
- Department of Tumor Biology, Institute for Cancer Research, Oslo, Norway
| | | | | | | | | | | |
Collapse
|
30
|
O'Han MK, Baxter RC, Schedlich LJ. Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors 2009; 27:394-408. [PMID: 19919528 DOI: 10.3109/08977190903185032] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
High tissue insulin-like growth factor binding protein-3 (IGFBP-3) expression in breast cancers is associated in some studies with rapid growth and poor outcome. This study examined the effects of endogenous IGFBP-3 in Hs578T breast cancer cells, which are IGF-unresponsive and grow aggressively despite relatively high IGFBP-3 expression. IGFBP-3 downregulation using siRNA was associated with increases in DNA synthesis, the percentage of cells in S phase and viable cell numbers, accompanied by increases in cyclins A and D1, a decrease in p27 expression, and increased phosphorylation of retinoblastoma (Rb) on Ser795. Downregulation of IGFBP-3 inhibited extracellular signal-regulated kinase (ERK) activation and cell migration in a monolayer wound healing assay. These results indicate that endogenous IGFBP-3 is anti-proliferative and pro-migratory in Hs578T cells and that these effects are IGF-independent. Poor outcome in breast tumours expressing high levels of IGFBP-3 may be due to the effects of IGFBP-3 on cell migration rather than cell growth.
Collapse
Affiliation(s)
- Michelle K O'Han
- Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, 2065, Australia
| | | | | |
Collapse
|
31
|
Akkiprik M, Hu L, Sahin A, Hao X, Zhang W. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer 2009; 9:103. [PMID: 19341485 PMCID: PMC2670316 DOI: 10.1186/1471-2407-9-103] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2008] [Accepted: 04/03/2009] [Indexed: 01/19/2023] Open
Abstract
Background Insulin-like growth factor binding protein 5 (IGFBP5) has been shown to be associated with breast cancer metastasis in clinical marker studies. However, a major difficulty in understanding how IGFBP5 functions in this capacity is the paradoxical observation that ectopic overexpression of IGFBP5 in breast cancer cell lines results in suppressed cellular proliferation. In cancer tissues, IGFBP5 resides mainly in the cytoplasm; however, in transfected cells, IGFBP5 is mainly located in the nucleus. We hypothesized that subcellular localization of IGFBP5 affects its functions in host cells. Methods To test this hypothesis, we generated wild-type and mutant IGFBP5 expression constructs. The mutation occurs within the nuclear localization sequence (NLS) of the protein and is generated by site-directed mutagenesis using the wild-type IGFBP5 expression construct as a template. Next, we transfected each expression construct into MDA-MB-435 breast cancer cells to establish stable clones overexpressing either wild-type or mutant IGFBP5. Results Functional analysis revealed that cells overexpressing wild-type IGFBP5 had significantly lower cell growth rate and motility than the vector-transfected cells, whereas cells overexpressing mutant IGFBP5 demonstrated a significantly higher ability to proliferate and migrate. To illustrate the subcellular localization of the proteins, we generated wild-type and mutant IGFBP5-pDsRed fluorescence fusion constructs. Fluorescence microscopy imaging revealed that mutation of the NLS in IGFBP5 switched the accumulation of IGFBP5 from the nucleus to the cytoplasm of the protein. Conclusion Together, these findings imply that the mutant form of IGFBP5 increases proliferation and motility of breast cancer cells and that mutation of the NLS in IGFBP5 results in localization of IGFBP5 in the cytoplasm, suggesting that subcellular localization of IGFBP5 affects its cell growth and migration functions in the breast cancer cells.
Collapse
Affiliation(s)
- Mustafa Akkiprik
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | | | | | | | | |
Collapse
|
32
|
Li M, Li Y, Lu L, Wang X, Gong Q, Duan C. Structural, gene expression, and functional analysis of the fugu (Takifugu rubripes) insulin-like growth factor binding protein-4 gene. Am J Physiol Regul Integr Comp Physiol 2008; 296:R558-66. [PMID: 19091910 DOI: 10.1152/ajpregu.90439.2008] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The insulin-like growth factor (IGF) signaling pathway is a conserved pathway that regulates animal development, growth, metabolism, reproduction, and aging. The biological actions of IGFs are modulated by IGF-binding proteins (IGFBPs). Although the structure and function of fish IGFBP-1, -2, -3, and -5 have been elucidated, there is currently no report on the full-length structure of a fish IGFBP-4 nor its biological action. In this study, we cloned and characterized the IGFBP-4 gene from fugu. Sequence comparison, phylogenetic, and synteny analyses indicate that its chromosomal location, gene, and protein structure are similar to its mammalian orthologs. Fugu IGFBP-4 mRNA was easily detectable in all adult tissues examined with the exception of spleen. Older animals tended to have higher levels of IGFBP-4 mRNA in the muscle and eyes compared with younger animals. Starvation resulted in significant increases in IGFBP-4 mRNA abundance in the muscle, liver, gallbladder, and brain. Overexpression of fugu and human IGFBP-4 in zebrafish embryos caused a significant decrease in body size and somite number, suggesting that fugu IGFBP-4 inhibits growth and development, possibly by binding to IGFs and inhibiting their binding to the IGF receptors. These results provide new information about the structural and functional conservation, expression patterns, and physiological regulation of the IGFBP-4 gene in a teleost fish.
Collapse
Affiliation(s)
- Mingyu Li
- Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA
| | | | | | | | | | | |
Collapse
|
33
|
Perks CM, Holly JMP. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 2008; 13:455-69. [PMID: 19031049 DOI: 10.1007/s10911-008-9106-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2008] [Accepted: 11/11/2008] [Indexed: 01/13/2023] Open
Abstract
The IGFBP family comprises six proteins with high affinity for the IGFs. Changes in the balance of the components of the IGF system may contribute to the progression of breast cancer. In tumours the abundance of IGFBPs relates to the estrogen receptor status and their production in the breast is controlled by hormones, principally estrogen and progesterone. Important interactions occur between IGFBPs and key growth regulators such as TGF-beta, PTEN and EGF which are reviewed. The conflicting observations between the effects of IGFBPs on the risk of breast cancer, in particular IGFBP-3, obtained from epidemiology studies in comparison to in vivo observations are highlighted and potential explanations provided. The functional activity of IGFBPs can also be affected by proteolysis, phosphorylation and glycosylation and the implications of these are described. The IGFs are generally present at levels far in excess of that required for maximal receptor stimulation, and the IGFBPs are critical regulators of their cellular actions. IGFBPs can affect cell function in an IGF-dependent or independent manner. The key mechanisms underlying the intrinsic actions of the IGFBPs are still in debate. IGF bioactivity locally in the breast is influenced not only by local tissue expression and regulation of IGFs, IGFBPs and IGFBP proteases, but also by these factors delivered from the circulation. Finally, the therapeutic potential of IGFBPs-2 and -3 are considered together with key questions that still need to be addressed.
Collapse
Affiliation(s)
- Claire M Perks
- Department of Clinical Sciences North Bristol, IGFs and Metabolic Endocrinology Group, University of Bristol, Southmead Hospital, The Medical School Unit, Bristol, BS10 5NB, UK.
| | | |
Collapse
|
34
|
Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin A, Krishnamurthy S, Ozer A, Hao X, Zhang W. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res 2008; 10:212. [PMID: 18710598 PMCID: PMC2575530 DOI: 10.1186/bcr2116] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The insulin-like growth factor axis, which has been shown to protect cells from apoptosis, plays an essential role in normal cell physiology and in cancer development. The family of insulin-like growth factor binding proteins (IGFBPs) has been shown to have a diverse spectrum of functions in cell growth, death, motility, and tissue remodeling. Among the six IGFBP family members, IGFBP-5 has recently been shown to play an important role in the biology of breast cancer, especially in breast cancer metastasis; however, the exact mechanisms of action remain obscure and sometimes paradoxical. An in-depth understanding of IGFBP-5 would shed light on its potential role as a target for breast cancer therapeutics.
Collapse
Affiliation(s)
- Mustafa Akkiprik
- Department of Medical Biology, Marmara University, School of Medicine, 34668 Istanbul, Turkey.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA. Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2008; 2:17-22. [PMID: 19088866 PMCID: PMC2577950 DOI: 10.2174/1874312900802010017] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Revised: 02/19/2007] [Accepted: 03/06/2008] [Indexed: 01/12/2023] Open
Abstract
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to halt the progression of fibrosis and potentially reverse it.
Collapse
Affiliation(s)
- Hidekata Yasuoka
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | | | | |
Collapse
|
36
|
Park JY, Park YH, Shin DH, Oh SH. Insulin-like growth factor binding protein (IGFBP)-mediated hair cell survival on the mouse utricle exposed to neomycin: the roles of IGFBP-4 and IGFBP-5. Acta Otolaryngol 2007:22-9. [PMID: 17882566 DOI: 10.1080/03655230701624822] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
CONCLUSION This study suggests for the first time that 1) IGF-I, IGFBP-4, and -5 alone and IGF-I+IGFBP-5 mixture stimulated hair cell survival and prevented neomycin-induced hair cell loss in the sensory epithelial culture of mouse utricles, 2) When administered together, IGFBP-4 diminished the effect of IGF-I, 3) In P3-5 mice utricle, IGF-I, IGFBP-4, and IGFBP-5 are expressed in the cytoplasm of hair cells. And Insulin/IGF-I Receptor is expressed in the nucleus of hair cells. OBJECTIVES Several growth factors have been demonstrated to protect auditory sensory cells in vitro and in vivo from aminoglycoside toxicity. IGF-I is one of the most well-known mitogenic and protective substance working in the inner ear. However, there are no reports available regarding the function of IGFBPs in the inner ear. In the present study, the effects of IGFBP-4 and -5 on hair cell survival were investigated in mouse utriclular organ cultures. MATERIALS AND METHODS The amount of cellular damage and cell viability in vestibular organs were assessed by counting hair cells stained with a rhodamine-phalloidin probe. The expressions of IGFBP-4, IGFBP-5, IGF-IR, and IGF-I were localized by immunohistochemistry. RESULTS When treated with IGF-I, IGFBP-4, or IGFBP-5 for 24 h, explant culture showed hair cell survival rates of 136+/-18%, 140+/-15%, and 133+/-6%, respectively, compared to controls. Neomycin (1 mM) induced hair cell loss resulted in 45+/-17% of hair cell survival. However, pre-treatment of IGF-I, IGFBP-4, or -5 before neomycin insult showed survival rates of 113+/-14%, 98+/-8%, and 73+/-24%, respectively. Similar to IGF-I, IGFBP-4 and IGFBP-5 were significantly protective. IGFBP-4 and -5 immunoreactivities were observed in the cytoplasm of normal explanted vestibular hair cells as well as in the P3 mouse utricular hair cells in vivo.
Collapse
Affiliation(s)
- Ji Yeong Park
- Department of Otorhinolaryngology, Seoul National University, Seoul, Korea
| | | | | | | |
Collapse
|
37
|
Subramanian A, Sharma A, Mokbel K. Insulin-like growth factor binding proteins and breast cancer. Breast Cancer Res Treat 2007; 107:181-94. [PMID: 17611793 DOI: 10.1007/s10549-007-9549-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2007] [Accepted: 02/12/2007] [Indexed: 11/30/2022]
Affiliation(s)
- Ashok Subramanian
- Department of Breast Surgery, St Georges Hospital NHS Trust, Blackshaw Road, Tooting, London, UK.
| | | | | |
Collapse
|
38
|
Insulin-like growth factors and breast cancer therapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2007; 608:101-12. [PMID: 17993235 DOI: 10.1007/978-0-387-74039-3_7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Despite improvements in breast cancer therapy in recent years, additional therapies need to be developed. New therapies may have activity by themselves or may have utility in combination with other agents. Population, preclinical, and basic data suggest the insulin-like growth factor (IGF) system functions to maintain the malignant phenotype in breast cancer. Since the IGFs act via transmembrane tyrosine kinase receptors, targeting of the key receptors could provide a new pathway in breast cancer. In addition, IGF action enhances cell survival, so combination of anti-IGF therapy with conventional cytotoxic drugs could lead to synergistic effects. In this review, we will discuss the rationale for targeting the IGF system, potential methods to disrupt IGF signaling, and identify potential interactions between IGF inhibitors and other anti-tumor strategies. We will also identify important issues to consider when designing clinical trials.
Collapse
|
39
|
Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006; 16:224-239. [PMID: 16893667 DOI: 10.1016/j.ghir.2006.06.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Antiestrogens target the estrogen receptor and counteract the growth stimulatory action of estrogen on human breast cancer. However, acquired resistance to antiestrogens is a major clinical problem in endocrine treatment of breast cancer patients. To mimic acquired resistance, we have used a model system with the antiestrogen sensitive human breast cancer cell line MCF-7 and several antiestrogen resistant cell lines derived from the parental MCF-7 cell line. This model system was used to study the expression and possible involvement in resistant cell growth of insulin-like growth factor binding protein 2 (IGFBP-2). By an oligonucleotide based microarray, we compared the expression of mRNAs encoding insulin-like growth factor binding protein 1,2,3,4,5 and 6 (IGFBP-1 to -6) in the parental MCF-7 cell line to three human breast cancer cell lines, resistant to the antiestrogen ICI 182,780 (Faslodex/Fulvestrant). Only IGFBP-2 mRNA was overexpressed in all three resistant cell lines. Thus, we compared the IGFBP-2 protein expression in MCF-7 cells to nine antiestrogen resistant breast cancer cell lines, resistant to either ICI 182,780 or tamoxifen or RU 58,668 and found that IGFBP-2 was overexpressed in all nine resistant cell lines. Three of the resistant cell lines, resistant to different antiestrogens, were selected for further studies and IGFBP-2 overexpression was demonstrated at the mRNA level as well as the intra- and extracellular protein level. The objective of this study was to examine if IGFBP-2 is involved in growth of antiestrogen resistant human breast cancer cells. Therefore, IGFBP-2 expression was inhibited by antisense oligonucletides and siRNA. Specific inhibition of IGFBP-2 protein expression was achieved in MCF-7 and the three selected antiestrogen resistant cell lines, but no effect on resistant cell growth was observed. Thus, we were able to establish IGFBP-2 as a marker for antiestrogen resistant breast cancer cell lines, although IGFBP-2 was not a major contributor to the resistant cell growth.
Collapse
Affiliation(s)
- A Juncker-Jensen
- Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
| | | | | | | | | | | |
Collapse
|
40
|
Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia 2006; 53:845-57. [PMID: 16586492 DOI: 10.1002/glia.20345] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
cAMP has been shown to reverse the transformed phenotype of various cancer cells. Human glioblastoma U87MG cells exposed to 500 microM dB-cAMP for 6 days showed reduced proliferation, attenuated invasiveness, and inability to induce angiogenic responses in human brain endothelial cells (HBECs) grown in Matrigeltrade mark. VEGF was the principal mediator of angiogenic actions of U87MG conditioned media (CM), since VEGF neutralizing antibody completely inhibited U87MG-induced angiogenic responses and no detectable levels of IGF, bFGF, and PlGF were found in U87MG CM. VEGF release was induced ( approximately 20%) in dB-cAMP-treated U87MG cells, suggesting a simultaneous induction of anti-angiogenic mediators. Down-stream effectors of dB-cAMP actions in U87MG were investigated by microarray gene expression analysis. Detected increases in differentiation genes, staniocalcin-1 and Wnt-5a, and angiogenesis-related genes, PAI-1, SPARC, IGFBP-4, IGFBP-7, PAPP-A, and PRSS-11 in dB-cAMP-treated U87MG cells were validated by real-time PCR, Western blot, and/or ELISA. A subsequent series of experiments identified IGFBP-4 as the principal anti-angiogenic mediator secreted by glioblastoma cells in response to dB-cAMP. Human recombinant IGFBP-4 inhibited the angiogenic response of HBEC induced by U87MG CM, whereas anti-human IGFBP-4 antibody restored the pro-angiogenic activity of dB-cAMP-treated U87MG CM. Since neither U87MG nor HBEC cells secreted detectable levels of IGF-I, and there are no known cellular IGFBP-4 receptors, the anti-angiogenic effect of IGFBP-4 was likely IGF-I-independent and indirect. IGFBP-4 also antagonized angiogenic effects of VEGF(165), PlGF, and bFGF, and reduced U87MG colony formation in soft-agar. IGFBP-4 is a novel dB-cAMP-induced anti-angiogenic and anti-tumorigenic mediator that may be a promising candidate for glioblastoma therapy.
Collapse
Affiliation(s)
- María J Moreno
- Cerebrovascular Research Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada.
| | | | | | | | | |
Collapse
|
41
|
Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006; 395:1-19. [PMID: 16526944 PMCID: PMC1409685 DOI: 10.1042/bj20060086] [Citation(s) in RCA: 161] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2006] [Accepted: 01/30/2006] [Indexed: 11/17/2022]
Abstract
The six members of the insulin-like growth factor-binding protein family (IGFBP-1-6) are important components of the IGF (insulin-like growth factor) axis. In this capacity, they serve to regulate the activity of both IGF-I and -II polypeptide growth factors. The IGFBPs are able to enhance or inhibit the activity of IGFs in a cell- and tissue-specific manner. One of these proteins, IGFBP-5, also has an important role in controlling cell survival, differentiation and apoptosis. In this review, we report on the structural and functional features of the protein which are important for these effects. We also examine the regulation of IGFBP-5 expression and comment on its potential role in tumour biology, with special reference to work with breast cancer cells.
Collapse
Key Words
- extracellular matrix (ecm)
- glycosaminoglycan
- insulin-like growth factor-i (igf-i)
- insulin-like growth factor-binding protein 5 (igfbp-5)
- mammary gland
- proteolysis
- adam, adisintegrin and metalloprotease
- ap-2, activator protein 2
- cat, chloramphenicol acetyltransferase
- cbp-4, c-terminus of insulin-like growth factor-binding protein 4 (residues 151–232)
- c/ebp, ccaat/enhancer-binding protein
- ecm, extracellular matrix
- er, oestrogen receptor
- erk1/2, extracellular-signal-regulated protein kinase 1/2
- fhl-2, four-and-a-half lim domain 2
- gag, glycosaminoglycan
- gh, growth hormone
- igf, insulin-like growth factor
- igfbp, igf-binding protein
- igf-ir, igf-i receptor
- igf-iir, igf-ii receptor
- ir, insulin receptor
- irs, ir substrate
- mapk, mitogen-activated protein kinase
- nbp-4, n-terminus of igfbp-4 (residues 3–82)
- oe2, oestradiol
- op-1, osteogenic protein-1
- opn, osteopontin
- pai-1, plasminogen activator inhibitor-1
- papp, pregnancy-associated plasma protease
- pge2, prostaglandin e2
- psmc, porcine smooth-muscle cell
- ra, retinoic acid
- rassf1c, isoform c of the ras association family 1 protein group
- rt, reverse transcription
- spr, surface plasmon resonance
- tpa, tissue plasminogen activator
- tsp-1, thrombospondin-1
- vn, vitronectin
Collapse
Affiliation(s)
- James Beattie
- Hannah Research Institute, Ayr KA6 5HL, Scotland, UK.
| | | | | | | |
Collapse
|
42
|
Abstract
Insulin-like growth factors (IGFs) are fundamental cell regulators with an evolutionary conserved role synchronising tissue growth, development and function according to metabolic conditions. Although structurally very similar to insulin, the IGFs act in a very different way as cell regulators. Whereas insulin is stored in a specific gland and released when needed, the IGFs are stored outside of cells with soluble binding proteins. A very complex system of six IGF binding proteins, each of which exists in various modified states and interacts with other proteins, provides a sophisticated system for conferring specificity to provide a finely tuned system for local regulation at the tissue level.
Collapse
Affiliation(s)
- Jeff Holly
- Department of Clinical Science at North Bristol, University of Bristol, Bristol, UK.
| | | |
Collapse
|
43
|
Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005; 333:1011-6. [PMID: 15964556 DOI: 10.1016/j.bbrc.2005.06.010] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2005] [Accepted: 06/01/2005] [Indexed: 11/30/2022]
Abstract
Proteolytic modification of insulin-like growth factor binding proteins (IGFBPs) plays an important physiological role in regulating insulin-like growth factor (IGF) bioavailability. Recently, we demonstrated that matrix metalloproteinase-7 (MMP-7)/Matrilysin produced by various cancer cells catalyzes the proteolysis of IGFBP-3 in vitro and regulates IGF bioavailability, resulting in an anti-apoptotic effect against anchorage-independent culture. In the present study, we investigated whether MMP-7 contributes to proteolysis of the other five IGFBPs, IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-6, and whether this results in phosphorylation of the IGF type 1 receptor (IGF-1R). MMP-7 cleaved all six IGFBPs, resulting in IGF-mediated IGF-1R phosphorylation, which was inhibited by EDTA treatment. These results suggest that MMP-7 derived from cancer cells can regulate IGF bioavailability in the microenvironment surrounding the tumor, where various kinds of IGF/IGFBP complexes are found, thereby favoring cancer cell growth and survival during the processes of invasion and metastasis.
Collapse
Affiliation(s)
- Michio Nakamura
- Pathology Division, National Cancer Center Research Institute East, Chiba, Japan
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer. Am J Clin Nutr 2005. [DOI: 10.1093/ajcn/82.2.277] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Sudha B Biddinger
- From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston, MA (SBB), and the Division of Endocrinology, Children’s Hospital, Boston, MA (SBB and DSL)
| | - David S Ludwig
- From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston, MA (SBB), and the Division of Endocrinology, Children’s Hospital, Boston, MA (SBB and DSL)
| |
Collapse
|
45
|
Wex H, Ahrens D, Hohmann B, Redlich A, Mittler U, Vorwerk P. Insulin-like Growth Factor-Binding Protein 4 in Children with Acute Lymphoblastic Leukemia. Int J Hematol 2005; 82:137-42. [PMID: 16146846 DOI: 10.1532/ijh97.e0429] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Insulin-like growth factor-binding protein 4 (IGFBP-4) is a potent inhibitor of IGF-mediated cell proliferation. To investigate the functional relevance of IGFBP-4 in leukemia, we measured plasma IGFBP-4 levels and messenger RNA expression in leukemic cell clones of patients with acute lymphoblastic leukemia (ALL) and in control subjects. The IGFBP-4 levels of ALL patients at diagnosis were significantly lower than the levels of healthy control subjects. We evaluated the patients at diagnosis and after 33 days of chemotherapy and found plasma IGFBP-4 levels at day 33 to be significantly lower than the levels at diagnosis. There was no correlation of plasma IGFBP-4 level with age, sex, immunophenotype, or ALL risk group, and there was no correlation of IGFBP-4 level with plasma IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3 levels. Gene expression analysis of the leukemic blast population at diagnosis revealed that the leukemic clones did not significantly contribute to systemic IGFBP-4 levels. The decrease in plasma IGFBP-4 levels during chemotherapy represents an indirect effect, probably caused by the chemotherapeutic effects on IGFBP-4-expressing cells of the liver and other organs. In addition, IGFBP-4 gene expression was investigated in 13 human immune cell-related cell lines by reverse transcription-polymerase chain reaction analysis. IGFBP-4 was exclusively expressed in cell lines derived either from B-cells or from myelomonocytic cells, whereas IGFBP-4 was not expressed in T-cell lines.
Collapse
Affiliation(s)
- Heike Wex
- University Otto von Guericke, Department of Pediatric Hematology and Oncology, Magdeburg, Germany
| | | | | | | | | | | |
Collapse
|
46
|
Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer. Am J Clin Nutr 2005; 82:277-8. [PMID: 16087968 DOI: 10.1093/ajcn.82.2.277] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Tanno B, Cesi V, Vitali R, Sesti F, Giuffrida ML, Mancini C, Calabretta B, Raschellà G. Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells. Cell Death Differ 2005; 12:213-23. [PMID: 15618969 DOI: 10.1038/sj.cdd.4401546] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Signal transduction through the IGF axis is implicated in proliferation, differentiation and survival during development and adult life. The IGF axis includes the IGF binding proteins (IGFBPs) that bind IGFs with high affinity and modulate their activity. In neuroblastoma (NB), a malignant childhood tumor, we found that IGFBP-5 is frequently expressed. Since NB is an IGF2-sensitive tumor, we investigated the relevance and the function of endogenous IGFBP-5 in LAN-5 and in SY5Y(N) cell lines transfected with micro and small interfering RNAs directed to IGFBP-5 mRNA. Cells in which IGFBP-5 expression was suppressed were growth-inhibited and more prone to apoptosis than the parental cell line and controls. Apoptosis was further enhanced by X-ray irradiation. The ability of these cells to undergo neuronal differentiation was impaired after IGFBP-5 inhibition but the effect was reversed by exposure to recombinant IGFBP-5. Together, these data demonstrate the importance of IGFBP-5 for NB cell functions and suggest that IGFBP-5 might serve as a novel therapeutic target in NB.
Collapse
Affiliation(s)
- B Tanno
- ENEA Research Center Casaccia, Biotechnology Unit, Section of Toxicology and Biomedical Sciences, Via Angullarese, 301, 00060 S. Maria di Galeria, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Insulin-like growth factor binding protein (IGFBP)-6 is unique among IGFBPs for its IGF-II binding specificity. IGFBP-6 inhibits growth of a number of IGF-II-dependent cancers, including rhabdomyosarcoma, neuroblastoma and colon cancer. Although the major action of IGFBP-6 appears to be inhibition of IGF-II actions, a number of studies suggest that it may also have IGF-independent actions. Gene array studies show regulation of IGFBP-6 in many circumstances that are consistent with antiproliferative actions. However, other studies show the opposite, so that IGFBP-6 may be acting as a counter-regulator in these situations or it may have other as yet undetermined actions. Both the N-terminal and C-terminal domains of IGFBP-6 contribute to high affinity IGF binding, and the C-terminal domain appears to confer its IGF-II specificity. The three-dimensional structure of the C-domain of IGFBP-6 contains a thyroglobulin type 1 fold, and the IGF-II binding site is located in the proximal half of this domain adjacent to the glycosaminoglycan binding site. Future studies are needed to further delineate the putative IGF-independent actions of IGFBP-6 and to build on the structural information to enhance our understanding of this IGFBP. This is particularly significant since IGFBP-6 provides an attractive basis for therapy of IGF-II-dependent tumors.
Collapse
Affiliation(s)
- Leon A Bach
- Department of Endocrinology and Diabetes, Alfred Hospital, Melbourne, Vic. 3004, Australia.
| |
Collapse
|
49
|
Chatterjee S, Park ES, Soloff MS. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 2005; 11:876-84. [PMID: 15479293 DOI: 10.1111/j.1442-2042.2004.00898.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Insulin-like growth factor binding protein-2 (IGFBP-2) is expressed by all human prostate cancer cell lines and dramatically increases in the serum of prostate cancer patients. However, the role of IGFBP-2 in prostatic tumorigenesis is not known. The aim of the present study was to investigate the effects of IGFBP-2 on the proliferation of DU145 human prostate cancer cells in culture. METHODS Using cell proliferation assays, we examined the effects of exogenously administered and endogenously modulated levels of IGFBP-2 on the proliferation of DU145 cells. RESULT Cell growth was stimulated by exogenously administered IGFBP-2, but significantly retarded (P < 0.05) by its neutralizing antibody. Overexpression of IGFBP-2 by transfection also stimulated cell growth, which was significantly (P < 0.05) inhibited in transfectants expressing antisense mRNA to IGFBP-2. Furthermore, the proliferation of IGFBP-2 overexpressing cells was significantly dampened by exogenously administered IGFBP-2 antibody. CONCLUSIONS IGFBP-2 is an autocrine growth factor for DU145 human prostate cancer cells and cell proliferation can be significantly retarded by neutralizing or inhibiting its synthesis. These findings provide a strong rationale for targeting IGFBP-2 in the testing of novel strategies to treat prostate cancer.
Collapse
Affiliation(s)
- Shilla Chatterjee
- Department of Obstetrics & Gynecology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1069, USA.
| | | | | |
Collapse
|
50
|
Reichling T, Goss KH, Carson DJ, Holdcraft RW, Ley-Ebert C, Witte D, Aronow BJ, Groden J. Transcriptional Profiles of Intestinal Tumors in Apc
Min Mice are Unique from those of Embryonic Intestine and Identify Novel Gene Targets Dysregulated in Human Colorectal Tumors. Cancer Res 2005. [DOI: 10.1158/0008-5472.166.65.1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The adenomatous polyposis coli (APC) tumor suppressor is a major regulator of the Wnt signaling pathway in normal intestinal epithelium. APC, in conjunction with AXIN and GSK-3β, forms a complex necessary for the degradation of β-catenin, thereby preventing β-catenin/T-cell factor interaction and alteration of growth-controlling genes such as c-MYC and cyclin D1. Inappropriate activation of the Wnt pathway, via Apc/APC mutation, leads to gastrointestinal tumor formation in both the mouse and human. In order to discover novel genes that may contribute to tumor progression in the gastrointestinal tract, we used cDNA microarrays to identify 114 genes with altered levels of expression in ApcMin mouse adenomas from the duodenum, jejunum, and colon. Changes in the expression of 24 of these 114 genes were not observed during mouse development at embryonic day 16.5, postnatal day 1, or postnatal day 14 (relative to normal adult intestine). These 24 genes are not previously known Wnt targets. Seven genes were validated by real-time reverse transcription-PCR analysis, whereas four genes were validated by in situ hybridization to mouse adenomas. Real-time reverse transcription-PCR analysis of human colorectal cancer cell lines and adenocarcinomas revealed that altered expression levels were also observed for six of the genes Igfbp5, Lcn2, Ly6d, N4wbp4 (PMEPA1), S100c, and Sox4.
Collapse
Affiliation(s)
- Tim Reichling
- 1Department of Molecular Genetics, Biochemistry and Microbiology, and
- 2Howard Hughes Medical Institute, University of Cincinnati College of Medicine and Divisions of
| | - Kathleen Heppner Goss
- 1Department of Molecular Genetics, Biochemistry and Microbiology, and
- 2Howard Hughes Medical Institute, University of Cincinnati College of Medicine and Divisions of
| | - Daniel J. Carson
- 1Department of Molecular Genetics, Biochemistry and Microbiology, and
| | | | | | - Dave Witte
- 4Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - Joanna Groden
- 1Department of Molecular Genetics, Biochemistry and Microbiology, and
- 2Howard Hughes Medical Institute, University of Cincinnati College of Medicine and Divisions of
| |
Collapse
|